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Host Determinants of Protection and Pathogenesis during Chikungunya Virus Infection 
by 
Lindsey Elaine Cook 
Doctor of Philosophy in Biology and Biomedical Sciences 
Immunology 
Washington University in St. Louis, 2018 
Professor Deborah J. Lenschow, Chairperson 
 Chikungunya virus (CHIKV) is a mosquito-transmitted alphavirus that causes acute and 
chronic polyarthritis. The virus has rapidly emerged over the last decade, and in 2013, CHIKV 
spread to the Western Hemisphere for the first time, infecting more than 1.8 million people. 
CHIKV targets the joints and musculoskeletal tissues, resulting in severe myalgia and symmetric 
polyarthritis that clinically mimics rheumatoid arthritis. Currently, no approved treatment is 
effective in preventing or controlling CHIKV infection or disease. Pathogenesis of CHIKV is still 
poorly understood but is thought to reflect an interplay between viral replication and detrimental 
immune responses. CHIKV patients have increased numbers of circulating CD4+ and CD8+ T 
cells, and mice lacking or depleted of CD4+ T cells show reduced foot swelling and arthritis during 
acute CHIKV infection, suggesting that CD4+ T cells contribute to the pathology of arthritis. 
Additionally, monocytes and/or macrophages are also thought to promote disease because 
depletion of macrophages with clodronate liposomes or inhibiting production of monocyte 
chemoattractant protein-1 (MCP-1) with bindarit improved symptoms in animal models. Though 
immunopathology appears to play an important role in CHIKV pathogenesis, not all host responses 
are detrimental. Central to controlling CHIKV and other alphavirus infections is the type I 
xii 
interferon (IFN-I) response, as mice lacking the IFN-I receptor rapidly succumb to infection. IFN-
I are well known for their antiviral and immunomodulatory properties, but their mechanism of 
action during CHIKV infection is poorly understood. 
 IFN-Is are composed of 14 IFN-α subtypes and single forms of IFN-β, IFN-ε, IFN-κ, and 
IFN-ω, and despite their central role in protection against a number of viruses, little is known about 
the biological roles of individual IFN-I subtypes during viral infection. To address this issue we 
used genetic deletion mutants and blockade with antibodies targeting specific IFN subtypes to 
determine the contributions of IFN-α and IFN-β during acute CHIKV infection. We found that 
both IFN-α and IFN-β play important protective roles in limiting clinical CHIKV disease, but they 
do so by distinct mechanisms. The loss of IFN-α (through IRF7 knockout or IFN-α blocking Abs) 
resulted in increased CHIKV replication and dissemination. In contrast, loss of IFN-β (through 
IFN-β knockout or IFN-β blocking Abs) had minimal impact on viral replication and 
dissemination.  Instead, the loss of IFN-β lead to increased neutrophil recruitment and elevated IL-
9 induction. Further, the increased clinical disease observed in IFN-β knockout mice could be 
rescued with neutrophil depletion. Thus, our findings suggest distinct protective roles for the IFN-
I subtypes during CHIKV infection, with IFN-α functioning to limit early viral replication and 
spread and IFN-β modulating neutrophil-mediated immunopathology. 
 Previous data have shown that immune cells and proinflammatory cytokines contribute to 
CHIKV arthritis in mice. Because chronic CHIKV arthritis is clinically similar to seronegative 
rheumatoid arthritis, we examined the efficacy of several U.S. Food and Drug Administration 
(FDA)-approved rheumatoid arthritis therapies in a mouse model of CHIKV infection. We 
identified CTLA4-Ig (abatacept) as a disease-modifying antirheumatic drug (DMARD) with 
efficacy during acute CHIKV arthritis. CTLA4-Ig, which blocks T cell activation, reduced T cell 
xiii 
accumulation in the joints of infected animals without affecting viral replication. When paired with 
the neutralizing anti-CHIKV human monoclonal antibody, 4N12, it was highly effective at 
reducing joint inflammation, periarticular swelling, migration of inflammatory leukocytes, and 
infection, even when administered several days after virus inoculation. Thus, combination of anti-
inflammatory and antibody-based antiviral therapy may serve as a model for treating humans with 
arthritis caused by CHIKV or other related viruses. 
 Collectively, these data provide important mechanistic insight into the host factors that 
control and promote CHIKV pathogenesis. Continued pursuit of defining interactions between 
CHIKV and the host immune responses will be paramount in developing effective therapeutics 
and vaccines to combat CHIKV and other emerging tropical diseases, which remain a global health 
and economic burden. 
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Chapter 1 
Introduction 
  
2 
1.1 Chikungunya virus 
1.1.1 Overview 
 Chikungunya virus (CHIKV) is a mosquito-transmitted alphavirus that causes acute and 
chronic polyarthritis. The virus has rapidly emerged over the last decade, with millions of people 
infected worldwide. CHIKV targets the joints and musculoskeletal tissues, resulting in severe 
myalgia and symmetric polyarthritis that can last for months to years after infection in some 
patients. Currently, no approved treatment is effective in preventing or controlling CHIKV 
infection or disease. Pathogenesis of CHIKV is still poorly understood but is thought to reflect 
interplay between viral replication and detrimental immune responses. 
1.1.2 Epidemiology and Transmission 
 CHIKV was first isolated from a febrile patient in Tanzania in 1952, and its name comes 
from a Makonde phrase that means “to become contorted” or “that which bends up,” which 
describes the posture of those suffering from debilitating CHIKV arthritis1. In endemic rural areas, 
CHIKV is maintained in an enzootic cycle involving nonhuman primates and mosquitoes, 
occasionally causing short-lived sporadic outbreaks in urban areas of Africa, which rely on human-
mosquito-human transmission2. Three lineages of CHIKV have been defined: East/Central/South 
African (ECSA), West African, and Asian. The West African strain has mostly been associated 
with enzootic transmission and occasional small outbreaks of human disease confined to West 
Africa. In contrast, the ECSA and Asian genotypes have rapidly expanded to new regions and have 
caused numerous urban outbreaks. 
 Beginning in 2004 a severe outbreak with the ECSA strain began in the coastal region of 
Kenya on Lamu Island and Mombasa. CHIKV then quickly spread to surrounding countries and 
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islands of the Indian Ocean. During this outbreak, the French island of La Réunion experienced a 
particularly severe outbreak, with over one third of the population infected with CHIKV between 
2005 and 20063,4. During the La Réunion outbreak, more severe disease manifestations, such as 
encephalopathy and mortality, were observed5,6. Studies comparing a clinical isolate from the La 
Réunion outbreak (LR OPY2006) to a previous strain (Senegal, 1983) revealed that increased 
infection of myofibers may have contributed to the increased disease severity seen on La Réunion7. 
When CHIKV re-emerged in India, millions of people were infected, and an infected traveler 
returning to Italy from India resulted in a small outbreak there, which was the first instance of local 
CHIKV transmission in Europe8. In 2013, the Asian strain of CHIKV emerged in the Caribbean 
on the island of Saint Martin, and since its introduction to the Americas, there have been over 1.8 
million suspected cases in South and Central America9. With its introduction to the Western 
Hemisphere, the United States has seen an increase in the number of imported cases, and for the 
first time, local transmission was reported in Florida10. 
 Historically, CHIKV was primarily transmitted by the Aedes aegypti mosquito, but in 2006 
the ECSA genotype acquired a single mutation (A226V) in its E1 envelope glycoprotein that 
enhanced its replication in the A. albopictus mosquito, which has more temperate geographical 
spread than A. aegypti11. Interestingly, the Asian strain is genetically constrained in its ability to 
adapt to the A. albopictus mosquito12. Transmission by A. albopictus played an important role in 
outbreaks that occurred in Italy, and increases the potential for outbreaks in other more temperate 
regions like the United States8. Despite the unprecedented rapid spread of the ECSA in the Indian 
Ocean region, it was the Asian lineage that emerged in the Caribbean and the Americas, and thus, 
the outbreaks in the Western Hemisphere have primarily been transmitted by A. aegypti. In 2014, 
the ECSA was reported to have been introduced in Brazil, raising concerns for the potential of 
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increased spread into the United States, where A. albopictus has great geographical range13. 
Collectively, in little more than a decade, CHIKV has reemerged as a global pathogen, infecting 
millions of people and causing economic damage in more than 50 countries2,14. 
1.1.3 Symptoms and Treatment 
 After being bitten by a mosquito carrying CHIKV and an incubation period of 2-6 days, 
infections in humans can manifest with fever, a maculopapular-like rash, malaise, myalgia, and 
severe polyarthralgia and polyarthritis15,16. During the ongoing outbreak, there was also reports of 
more severe symptoms, particularly in neonates, the elderly, or patients with other underlying 
medical conditions. These severe clinical features include neurologic and cardiac manifestations, 
and for the first time, there were reports of fatality associated with CHIKV infection5,6. Unlike 
other arthritogenic viruses, CHIKV infections are 90-95% symptomatic17. Patients presenting with 
acute CHIKV arthralgia usually experience symmetrical joint pain in the peripheral joints, such as 
wrists, knees, ankles, and the small joints of the hand. Joint pain is often accompanied with 
arthritis, with joints displaying swelling and tenderness. Acute disease is usually self-limiting and 
typically resolves in 7-10 days, however a large subset of patients can develop chronic symptoms 
that last from months to years after infection. There are reports that anywhere from 20 to 60% of 
infected individuals can develop chronic arthritis symptoms following CHIKV infection18–21. 
Epidemiological predictions suggest that the number of people in the Americas suffering from 
chronic CHIKV symptoms is 400,00022. Chronic CHIKV arthritis is clinically similar to patients 
with seronegative rheumatoid arthritis (RA), with the hands, wrists, feet, and ankles primarily 
affected23. 
 There are currently no approved specific antiviral therapies or vaccines available for 
CHIKV infection. Treatment for acute and chronic symptoms is primarily supportive care to 
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reduce fever and pain. A couple of small studies have reported improvement of CHIKV symptoms 
with chloroquine phosphate treatment, an antimalarial drug, but a study with a large cohort of 
patients from La Réunion found no improvement24–26. In recent years, studies have begun to 
address the need for new therapeutic options in CHIKV infection. A number of compounds have 
been showed to inhibit CHIKV replication in cell culture, and several treatment strategies in animal 
models of CHIKV infection have provided some hope for alleviation of CHIKV symptoms27. 
Monoclonal neutralizing antibodies isolated from infected patients have been protective when 
administered prophylactically or therapeutically in highly susceptible neonatal mice or 
immunocompromised mice28,29. Furthermore, a loss-of-function screening approach identified a 
number of pro-viral host factors with pre-existing small-molecule inhibitors available30. Several 
of these small-molecule inhibitors were efficacious in vivo, and the protective effects were 
enhanced when used in combination. Collectively, these studies demonstrate that targeting viral 
and/or host pathways may be promising, but much work remains to be done to develop and test 
effective treatment options for those suffering with CHIKV arthritis, particularly for those 
suffering from chronic symptoms. 
1.1.4 Replication Cycle 
 CHIKV and other alphaviruses are members of the Togaviridae family of viruses, and as 
such, they are enveloped viruses with a positive-sense, single stranded RNA genome. The CHIKV 
genome is approximately 11,800 base pairs in length and contains a 5’ untranslated region, 
followed by nonstructural genes, structural genes with a subgenomic promoter, and a 3’ 
untranslated region. Replication in mammalian cells takes place in the cytosol and in virally-
induced cytopathic vacuoles31. The replication cycle of CHIKV is summarized in Figure 1.1. 
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 Alphaviruses enter susceptible cells by clathrin-mediated endocytosis, but the specific 
mechanistic events for CHIKV binding and entry are still unclear32. Bona fide receptors have yet 
to be identified, but glycosaminoglycans may serve as attachment factors for many susceptible cell 
types33–35. Once CHIKV enters the endosomal compartment, the increased acidic environment 
inside the endosome induces a conformational change in the virion envelope that exposes the E1 
glycoprotein fusion loop36. This allows fusion of the virion envelope with the endosome 
membrane, releasing the nucleocapsid into the cytosol. Alphavirus capsid proteins bind the host’s 
large ribosomal subunit, and this interaction is thought to actively disassemble the nucleocapsid 
and release the RNA genome into the cytosol37,38. 
 The CHIKV genome contains two open reading frames that encode for two polyproteins, 
which are then cleaved into multiple proteins. First, the genome is translated by host machinery to 
produce the nonstructural polyprotein P1234. This precursor is autocleaved by protease activity 
located in nsP2 into P123 and nsP4, which make up a short-lived replicase that synthesizes a full-
length negative-sense RNA template31. Early negative-strand synthesis by the short-lived 
P123/nsP4 replicase takes place at the plasma membrane in small, vesicular compartments called 
spherules for a number of alphaviruses, including CHIKV39–43. The nsPs localize at the neck of 
the spherules, which might serve to help shield double-stranded RNA (dsRNA) intermediates from 
recognition by the host. The spherules are eventually internalized into large cytopathic vacuoles 
(CPV-I), and P123 accumulation leads to complete processing of the polyprotein into nsP1, nsP2, 
and nsP3, which together with nsP4 uses the negative-sense template for amplification of genomic 
positive-sense RNA and transcription of subgenomic (26S) positive-sense RNA that encodes the 
structural polyprotein. 
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 The host machinery begins to translate the subgenomic RNA, and as the capsid protein is 
translated, it is quickly released by autoproteolysis to begin forming nucleocapsids containing a 
single genomic RNA molecule. Translation of the subgenomic RNA continues to generate an E3-
E2-6K-E1 product and a minor product (E3-E2-TF) that is the result of ribosomal 
frameshifting44,45. The N-terminus of E3 contains a signal peptide that directs the 2 polyprotein 
products into the host secretory pathway, and host protease cleavage yields pE2 (E3-E2), 6K or 
transframe (TF), and E1. The roles of 6K and TF are still unclear. They do not seem to be 
incorporated into virions, but may have ion-channel properties and play important roles in viral 
budding46. E1 and E3-E2 continue through the secretory pathway and undergo several post-
translational modifications, including N-linked glycosylation, and E3 is released by the host 
protease furin. E1 and E2 can now begin to form spikes on the plasma membrane31. 
 A second type of cytopathic vacuole (CPV-II) forms late in infection. Here, cytoplasmic 
nucleocapsids associate with internalized E1 and E2 spikes, and a mature virion egresses and buds 
from the cell47,48. It is worth noting that CPV-I and CPV-II formation appears to be specific to 
mammalian cells infected with CHIKV. The CHIKV virion contains a lipid bilayer envelope 
around an icosahedral nucleocapsid shell, which consists of 240 capsid copies and the genomic 
RNA. The E1 and E2 glycoproteins form heterodimers on the envelope surface that are further 
arranged into trimers to form an icosahedral lattice49. There is some evidence that CHIKV may be 
spread by apoptotic blebs to uninfected neighboring cells in vitro, which would help avoid 
detection by antibodies and aid infection of some non-permissive cells. Macrophages were 
demonstrated to be infected after phagocytosing CHIKV-containing apoptotic blebs in vitro50. 
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1.1.5 Animal Models 
 In the last 10-15 years, significant progress has been made to delineate the mechanisms 
underlying disease pathogenesis. These advances have been made possible with the development 
and use of animal models that recapitulate many aspects of human disease. The most commonly 
used model is a mouse model of CHIKV arthritis. In this model adolescent and adult 
immunocompetent mice are inoculated with CHIKV directly into the rear footpad, mimicking the 
effects of a mosquito bite. This arthritis mouse model recapitulates many aspects of acute human 
disease including viremia, viral replication in the joint and muscle tissues, and histopathological 
signs of synovitis and myositis51–53. This route of CHIKV infection in mice causes a biphasic 
pattern of foot swelling in the inoculated foot. In a WT mouse, the first peak of foot swelling occurs 
2-3 days post infection (dpi) and is thought to arise from robust viral replication which drives cell 
death, local proinflammatory cytokine production, and edema. The second peak (6-7 dpi) occurs 
as infectious virus is cleared from the tissues and blood and is associated with an influx of 
inflammatory infiltrates into the joint spaces and surrounding soft tissues that drive cytokine 
production, synovitis, myositis, and edema51,52. Though clinical foot swelling resolves by 10-12 
dpi, this model does encompass some aspects of chronic CHIKV disease. CHIKV RNA persists 
in the joints of mice to at least 120 dpi, and there are signs of myositis and synovitis by 
histopathology54,55. The pathogenesis of CHIKV in the arthritis model is further discussed in 
section 1.1.7 and summarized in Figure 1.2 
 Other animal models have also been useful in determining mechanisms of CHIKV 
pathogenesis. Infection of neonatal mice results in severe CHIKV disease that exhibits age-
dependent mortality. The severe symptoms observed in neonatal mice mimics many aspects of 
human infants infected with CHIKV, including dissemination to the central nervous system56–58. 
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Infection of adult cynomolgus macaques results in high viremia, viral dissemination, viral 
persistence, and pathological features similar to human disease, and aged rhesus macaques show 
persistent virus in the spleen59,60. The cumulative work from all of these models reveal that CHIKV 
symptoms are the result of both extensive viral replication in the musculoskeletal and joint tissues, 
as well as pathology driven by aspects of the host immune response (described in detail below). 
Careful mapping of the viral and host determinants of pathogenesis will be needed to aid in the 
development of effective therapeutics and vaccines to combat this global pathogen. 
1.1.6 Tropism 
Tropism: Cell Culture 
 When the severe CHIKV outbreak began in 2004, very little was known about CHIKV 
biology. Early work sought to define the cell tropism of CHIKV in vitro. An early study tested a 
large panel of immortalized and primary human cells for their ability to support CHIKV 
replication61. They demonstrated that a variety human epithelial-derived cell lines, such as HeLa 
and 293T cells, and primary fibroblasts (Hs 789.sk skin cells and MRC5 lung cells) were highly 
susceptible to CHIKV infection. Additionally, an endothelial cell line isolated from bone marrow 
(TrHBMEC cells), but not the brain (hCMEC/D3 cells), supported CHIKV replication. CHIKV 
infection of cell lines and primary cells was highly cytopathic and associated with apoptosis. In 
contrast, CHIKV did not replicate in lymphoid and monocyte cell lines, primary lymphocytes and 
monocytes, or monocyte-derived dendritic cells. In this study, primary monocyte-derived 
macrophages were the only immune cell population tested that was able to support CHIKV growth, 
albeit to a much lesser extent than the epithelial and fibroblast cells61. Because the skin is the first 
site of infection, another group sought to determine the response of keratinocytes to CHIKV 
infection and found that human keratinocytes are refractory to CHIKV infection at a post-fusion 
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step, but they were still able to produce cytokines and chemokines following CHIKV exposure62. 
Additional work has shown that CHIKV can also infect primary human osteoblast cultures, which 
leads to the production IL-6 and receptor activator of nuclear factor kappa-Β ligand (RANKL) and 
inhibition of osteoprotegerin63. 
Tropism: Acute Infection 
 After inoculation of immunocompetent mice in the skin, CHIKV RNA was detected by in 
situ hybridization in the ipsilateral foot at 3 days post infection (dpi) in cells lining blood vessels, 
skeletal muscle cells, cells in the dermis consistent with fibroblast morphology, cells in the 
synovial membrane, and cells of the periosteum64. By 5 dpi, the cells lining the blood vessels 
remained positive, but staining was diminished in the dermis and absent in the muscle. These data 
and the observations from cell culture infections suggest that CHIKV targets a wide variety of 
cells in the musculoskeletal and joint tissues, which is consistent with the clinical disease 
manifestations. Whether immune cells, particularly monocytes and macrophages, are actively 
infected during acute CHIKV infection remains unclear and controversial. Work from Lisa Ng’s 
group showed that monocytes isolated from viremic patients were positive for CHIKV antigen 
staining by flow cytometry, and this antigen positivity was lost when the samples were taken from 
the same patients during the chronic phase65. However, time-course analysis of infection of human 
monocytes in vitro suggest that monocytes might not support productive release of infectious 
particles. Over time, the percent of infected monocytes marginally increased over the 0 hour time 
point (35% versus 10%). Additionally, the viral load determined by RT-PCR remains constant 
over time, and infectious virus in the supernatant substantially decreases over time65.Though the 
authors concluded that monocytes could “sustain virus growth,” these data are more consistent 
with a model in which CHIKV can bind and enter monocytes, but this ultimately yields a 
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nonproductive infection. Nonproductively infected cells can be important sources of cytokines and 
chemokines, and it may be that nonproductive-infected monocytes are important sources of IFN-I 
(further discussed in section 1.2.4). 
Tropism: Chronic Disease 
 Tropism for chronic CHIKV infection is still not well understood. CHIKV has not been 
cultured from patient synovial fluid, but a biopsy of synovial tissue from a patient experiencing 
chronic symptoms showed CHIKV antigen-positive perivascular macrophages and large numbers 
of activated CD56+CD69+ NK cells and CD4+ T cells clustered around the CHIKV+ macrophage66. 
Additionally, aged rhesus macaques show CHIKV RNA persistence in their spleens, and 
additionally, a study with cynomolgus macaques showed that macrophages in the spleen were 
positive for CHIKV antigen59,60. These studies suggest that persistent viral RNA and/or antigen 
may be sustaining immune activation, which promotes continuous proinflammatory cytokine and 
chemokine production. The sensitivity of assays used to detect CHIKV antigen or viral RNA has 
made it difficult to identify the source and nature of persistent CHIKV RNA. Unpublished data 
from our lab using a CHIKV-Cre fate-reporter system suggest that while CHIKV is highly 
cytopathic in vitro, many cells are able to survive CHIKV infection in vivo. These cells seem to be 
CD45-negative and are mostly located in the muscle and to a lesser extent in the dermis. Much 
more work is needed to characterize the cellular players in harboring persistent CHIKV RNA. 
1.1.7 Pathogenesis 
Acute Pathogenesis: Innate Immune Responses 
 Evidence from patient samples and from animal models suggest that a robust innate 
immune response is mounted following CHIKV infection. Several groups have characterized 
proinflammatory cytokines and chemokines from serum of CHIKV patient cohorts. There have 
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been some discrepancies between the various cohorts, but IL-1β, IL-6, IFN-α, CCL2/MCP-1, 
CXCL9/MIG, and CXCL10/IP-10 are among those that were upregulated in CHIKV patients 
relative to healthy controls67–69. Macrophages and monocytes are rapidly recruited to the site of 
infection in animal models52. Clodronate depletion of macrophages had a protective effect on 
clinical disease, but worsened viremia, suggesting the macrophages may have a dual role in 
promoting pathogenesis while also controlling viral replication51. Consistent with this, a study 
showed that treatment with Bindarit, an inhibitor of CCL2 synthesis, reduced cellular infiltration 
and CHIKV-associated bone loss70. However, the role of macrophages and monocytes may be 
more complex, as mice deficient for CCR2, the receptor for CCL2, developed much more severe 
and prolonged CHIKV arthritic disease that was due to compensatory recruitment of neutrophils 
and eosinophils71. Indeed, recent work demonstrated that monocytes were protective in both RRV 
and CHIKV infection due to their type I interferon production (discussed in section 1.2.4)72. More 
careful characterization of infiltrating myeloid cells and their effector functions during CHIKV 
infection will be valuable for clarifying these findings. 
 Natural killer (NK) cells also infiltrate into the joint and muscle tissues following CHIKV 
infection52. Two separate studies have identified elevated NK cell percentage or activation in 
PBMCs isolated from patients73,74. Careful evaluation of the function of NK cells during CHIKV 
pathogenesis has not been done, but one study did note that NK cells mediated worse disease with 
an East-Central-South-African (ECSA) genotype of CHIKV, but not with an Asian lineage of 
CHIKV, suggesting that there might be strain-specific effects of NK cell involvement in 
pathogenesis75. Another innate-like cell type often involved in skin immune responses is γδ T cells. 
One study showed that TCRγδ-KO mice had worsened foot swelling at 7 dpi, accompanied with 
elevated proinflammatory cytokines and altered cellular recruitment, but no change in viral load 
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was observed76. This finding implies a protective immunomodulatory role for γδ T cells in CHIKV 
infection. Innate lymphoid cells are involved in a number of acute inflammatory models, including 
RA, but they have not been evaluated in CHIKV pathogenesis77. 
Acute Pathogenesis: Adaptive Immune Responses 
 Adaptive immune responses are involved in both protection and pathogenesis during 
CHIKV disease. Neutralizing antibodies are required for clearing infectious virus, whereas CD4+ 
T cells play a critical role in promoting pathogenesis. This is demonstrated in Rag1-/- mice, which 
fail to control viremia and sustain infectious virus replication in their periphery for greater than 3 
months post infection54. Coincidentally, Rag1-/- animals are also largely protected from clinical 
disease. Further characterization, of CD4-KO and CD8-KO mice determined that it was CD4+ T 
cells contributing to pathogenesis and antibodies responsible for clearing virus, whereas CD8+ T 
cells seem to be dispensable. Passively administering CHIKV neutralizing antibodies to Rag1-/- 
mice eliminates infectious virus, but after administration was stopped, infectious virus re-emerged, 
suggesting that neutralizing antibodies are able to control, but not clear CHIKV54,55. A pathogenic 
role for CD4+ T cells is reinforced with the observation that expansion of T regulatory cells with 
an IL-2/anti-IL-2 complex prior to CHIKV infection alleviated disease by inhibiting CHIKV-
specific effector CD4+ T cells78. These findings from animal models are supported by a study of a 
patient cohort, which found greater percentages of activated effector CD4+ and CD8+ T cells in 
peripheral blood mononuclear cells (PBMCs) isolated from patients with persistent CHIKV 
polyarthritis and patients with untreated, active rheumatoid arthritis (RA) compared to healthy 
controls23. Taken altogether, there is profound evidence that adaptive immune responses play 
important roles in the early stages of acute CHIKV disease. 
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Chronic pathogenesis 
 It is known that CHIKV RNA, but not infectious virus, persists in the joints and 
musculoskeletal tissues of patients and animals infected with various strains of CHIKV52,55,66. 
Furthermore, mice infected with a CHIKV strain engineered to express firefly luciferase still 
showed bioluminescence at chronic time points79. It is possible that this persistent RNA is 
continuously stimulating an inflammatory response. Consistent with this theory, a number of IFN-
related and proinflammatory genes were upregulated in CHIKV-infected foot tissue at 30 dpi 
compared to day 0 samples55. High levels of IFN-α was observed in PBMCs isolated from chronic 
CHIKV patients, and another group found that persistent arthralgia was associated with elevated 
levels of IL-6 and GM-CSF66,68. There is still much to be done to delineate the mechanisms of 
chronic CHIKV pathogenesis. 
1.2 Type I Interferons 
1.2.1 Overview 
 Type I interferons (IFN-I) are a family of multifunctional cytokines originally named for 
their ability to interfere with viral replication in vitro, and now they are recognized as major 
effector cytokines with important roles in both innate and adaptive immune responses80,81. General 
properties of IFN-I include eliciting an antiviral state through the induction of interferon stimulated 
genes (ISGs) and modulating innate and adaptive immune responses through both direct and 
indirect effects. IFN-I in mice consist of 14 IFN-α subtypes and single forms of IFN-β, IFN-ε, 
IFN-κ, and IFN-ω. Despite signaling through a shared receptor and possessing a similar spectrum 
of functions, in vitro studies and recent work in vivo highlight that there are different potencies of 
shared functions and some unique properties among the individual subtypes. The multigene nature 
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of IFN-I is conserved across many species, suggesting that having multiple IFN subtypes is 
beneficial for the host. 
1.2.2 Induction 
 Host cells possess many cell intrinsic and cell extrinsic mechanisms for detecting a viral 
infection and coordinating an IFN-I response. Pattern recognition receptors (PRRs) detect 
conserved pathogen-associated molecular patterns (PAMPs), such as nucleic acids during viral 
infection82. The nucleic acid sensors can be found in the cytosol of many cell types or in specialized 
endosomal compartments of immune cells and some nonhematopoietic cells83,84. Nucleic acid-
sensing PRRs are able to induce IFN-I through several distinct pathways, depending on the sensor 
and cell type, but most pathways ultimately converge on the activation of IRF3 or IRF7 
(summarized in Figure 1.3)82,85. 
DNA Sensors 
 Cytosolic sensors of DNA include DNA-dependent activator of IFN-regulatory factors 
(DAI)86 and cyclic GMP-AMP synthase (cGAS)87,88, whereas Toll-like receptor 9 (TLR9) 
recognizes cytosine-guanosine motifs in DNA within endosomes89. Most cytosolic DNA sensor 
signaling pathways converge on the activation of stimulator of IFN genes (STING), which is 
located on the endoplasmic reticulum. Activation of STING results in the phosphorylation and 
activation of TANK-binding kinase 1 (TBK1)90. TBK1 phosphorylates IRF3 or IRF7, allowing for 
their translocation into the nucleus. In contrast, TLR9 signals through MyD88 (myeloid 
differentiation primary response 88) to activate the E3 ubiquitin ligase TRAF6 (TNF receptor 
associated factor 6). TRAF6 can then induce proinflammatory cytokines via the activation of NF-
κB (nuclear factor kappa-light-chain-enhancer of activated B cells) or induce type I IFN production 
through IRF7 activation91. 
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RNA Sensors 
 Cytosolic RNA sensors include retinoic acid-inducible gene I (RIG-I), which recognizes 
short dsRNA and RNA with 5’ triphosphate ends and melanoma differentiation-associated protein 
5 (MDA5), which detects long dsRNA91. TLR3 and TRL7/8 are located in endosomes and 
recognize dsRNA and single-stranded RNA, respectively82. RIG-I and MDA5 signal through 
mitochondrial antiviral-signaling protein (MAVS), which when associated with the mitochondria 
leads to IFN-I induction via TBK1-mediated activation of IRF3/7, whereas when it is associated 
with the peroxisome, it leads to induction of a distinct set of antiviral genes. TLR3 signals through 
TRIF (TIR-domain-containing adapter-inducing interferon-β) to induce IFN-I downstream of 
TBK1-mediated activation of IRF391. 
IRF3 and IRF7 
 Initially, most cells respond to PRR signals to activate interferon regulatory factor 3 (IRF3), 
which can act on the promoters of the IFN-β and IFN-α4 subtypes92,93. These initial IFN-I subtypes 
signal in autocrine and paracrine means to modulate expression of ISGs that include antiviral 
effector molecules and regulators that promote the antiviral response. IRF7 is among the 
transcriptional regulators induced by the early IFN-I subtypes, and it participates in a positive 
feedback loop that induces the other IFN-α subtypes, thus amplifying and diversifying the IFN-I 
response (Figure 1.4)94,95. The central role of IRF7 in inducing the IFN-α subtypes is demonstrated 
in IRF7 deficient mice, which fail to produce many of the IFN-α subtypes in response to viral 
infection, including CHIKV64,96–98. A recent study from the laboratory of Jean-Laurent Casanova 
identified a compound heterozygous null mutation in IRF7 in a patient who suffered from a life-
threatening primary influenza A infection99. The patient’s leukocytes and plasmacytoid DCs 
(pDCs) produced very little type I and type III interferons and supported higher viral replication 
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in response to influenza infection; however, IFN-β was still mildly induced in the patient’s 
stimulated cells. Thus, IRF7 is a master regulator of IFN-I, particularly IFN-α subtypes, in both 
mice and humans. An exception to this IRF7 paradigm is pDCs, which are specialized cells of the 
immune system capable of producing large amounts of IFN-I during a viral infection100. Unlike 
most other cell types, pDCs constitutively express IRF7, enabling them to produce large amounts 
of IFN-α subtypes directly downstream of TLR7 or TLR9 signaling. The importance of pDCs for 
production of IFN-I during an infection can depend on the route of infection (systemic versus 
peripheral) and tropism of the virus101,102. 
1.2.3 Signaling 
 All type I IFN subtypes bind to and signal through a shared heterodimeric IFN-α/β receptor 
(IFNAR), which is composed of the subunits IFNAR1 and IFNAR2. IFNAR expression is fairly 
ubiquitous, enabling most cell types to respond to IFN-I. Ligand binding of IFNAR induces a 
conformational change in the receptor that causes auto-phosphorylation and activation of the 
tyrosine kinases Janus kinase 1 (JAK1) and tyrosine kinase 2 (TYK2), which are constitutively 
associated with IFNAR2 and IFNAR1, respectively103. Activated JAK1 and TYK2 then regulate 
the phosphorylation and activation of various signal transducer and activator of transcription 
(STAT) proteins104. 
 In canonical IFN-I signaling, STAT1 and STAT2 are phosphorylated and then form a 
complex with IRF9. This complex is called the IFN-stimulated gene (ISG) factor 3 (ISGF3), which 
can enter the nucleus and bind to IFN-sensitive response elements (ISREs) in the promoters of 
ISGs104. Type I IFN signaling can also regulate genes downstream of type II IFN (IFN-γ) by 
phosphorylating and activating STAT1 homodimers that bind to IFN-γ-activated site (GAS) 
enhancer elements in the promoters of some ISGs105. Additional C-terminal serine phosphorylation 
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of STAT1 and STAT2 is required for full transcriptional activation of ISGs but is not required for 
STAT nuclear translocation or DNA binding106,107. Ultimately, IFN-I signaling culminates in 
transcriptional regulation of hundreds of genes. These ISGs function to elicit an antiviral state in 
infected and neighboring cells. IFN-I are also known to have immunomodulatory and pleiotropic 
effects, depending on the cell type and context108. 
 There are many pathways independent of STAT activation that are induced upon IFN-I 
stimulation, and these pathways play important roles in regulating the pleiotropic effects of IFNs. 
In brief, TYK2-mediated phosphorylation of the scaffolding protein insulin receptor substrate 1 
(IRS1) allows for activation of the PI3K (phosphatidylinositol-4,5-bisphosphate 3-kinase) 
pathway, resulting in a broad range of biological effects including interleukin-10 (IL-10) 
production and protein kinase C delta (PKC-δ) activation109,110. PKC-δ is thought to be important 
in serine phosphorylation of STATs, as pharmacological inhibition of PI3K blocks STAT1 
phosphorylation at Ser727 and reduces STAT1-dependent transcription111. TYK2 can also recruit 
and phosphorylate the adaptor molecule CRKL (Crk-like protein), leading to the activation of the 
p38 MAPK (mitogen-activated protein kinase) pathway, which is required for IFN-I-mediated 
production of genes under ISRE and GAS regulation112. 
1.2.4 IFN-I Induction during CHIKV Infection 
 CHIKV has evolved mechanisms to counteract IFN-I action, highlighting the importance 
of IFN-I in combating CHIKV. CHIKV nsP2 translocates into the nucleus and degrades the host 
RNA polymerase II subunit RPB1, which results in general host cell transcriptional shut-off and 
cytopathic effects in mammalian cells113. Additionally, nsP2 is able to directly antagonize IFN-I 
signaling by preventing phosphorylated STAT1 from entering the nucleus by mechanisms that are 
still unclear114,115. Despite this antagonism, human patients infected with CHIKV mount a robust 
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innate immune response, including the induction of IFN-I and other cytokines and chemokines, 
and this is recapitulated in animal models56,58. 
Nonhematopoietic Cells Induce IFN-I via MAVS 
 Most cells are able to produce IFN-I in vitro, but induction in vivo is more complicated. 
One study generated a series of BMCs to characterize cell type-dependent PRR pathways 
responsible for IFN-I induction in vivo97. IRF3/7 DKO mice fail to make sufficient IFN-I and 
succumb to CHIKV infection with slightly delayed kinetics compared to IFNAR1-KO mice. DKO 
 WT BMCs were able to survive infection and control viral dissemination, indicating a role for 
nonhematopoietic cells in producing IFN-I during CHIKV infection. In vitro evidence indicated 
that MAVS is critical for IFN-I induction in mouse embryonic fibroblasts (MEFs) following 
CHIKV infection116. Although DKO  MAVS-/- BMCs survive infection, they showed enhanced 
viremia and dissemination. In contrast, the viral loads in MAVS-/-  DKO BMCs were almost 
identical to that of WT  DKO. These findings suggest that MAVS plays an antiviral role in 
nonhematopoietic cells, but is less important for IFN-I responses in hematopoietic cells. An 
antiviral role for MAVS pathways is further demonstrated in MAVS global knockout mice, which 
develop more severe clinical disease and enhanced viral replication64,116. It is also worth noting 
that RIG-I-/- or MDA5-/- mice do not show these clinical or virologic phenotypes, suggesting that 
RIG-I and MDA5 have redundant roles in CHIKV infection. 
Hematopoietic Cells Induce IFN-I 
 There is also evidence that immune cells can produce IFN-I during CHIKV infection. WT 
 DKO BMCs were able to survive infection and only showed limited increase in viral 
dissemination compared to WT  WT BMCs97. These results demonstrate that hematopoietic 
cells can be a sufficient source of IFN-I to effectively control CHIKV infection. That same study 
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performed multiple BMCs to determine the hematopoietic-specific PRR pathways responsible for 
protecting DKO recipients that fail to induce sufficient IFN-I. TLR7-/-  DKO and MyD88-/-  
DKO BMCs survived infection and controlled viral replication similarly as WT  DKO BMCs. 
This was surprising, given that MyD88-/- mice develop worse clinical disease and mildly worse 
viral loads compared to WT mice64,116. These data suggest that hematopoietic cells induce 
sufficient IFN-I for DKO recipients via a MyD88-independent pathway. 
 Several studies have characterized the role of TLR3 during CHIKV infection and found 
conflicting results. One group reported increased viremia and worsened clinical disease, 
characterized by severe infiltration of neutrophils and F4/80+ macrophages/monocytes in TRL3-/- 
mice117. This group also generated TLR3-/-  WT BMCs which recapitulated the viremia in the 
TLR3 global knockout mice, but showed no change in clinical disease. This suggests that TLR3 
may have an antiviral role in immune cells and an anti-inflammatory role in nonhematopoietic 
cells. Strikingly, a second group reported no virologic phenotype in TLR3-/- mice, but this 
discrepancy could be due to differences in route of infection or the age of animals116. An antiviral 
role for TLR3, is supported by the observation that TRIF-/- mice develop worse foot swelling and 
viremia after CHIKV infection64. All together, these data suggest that in immune cells, TLR3 may 
play an antiviral role by means of a MyD88-independent, TRIF-dependent pathway. There also 
seems to be a role for MyD88 in nonhematopoietic cells that impacts clinical disease but not viral 
load. These effects could be mediated downstream of IL-1β, which also signals via MyD88. More 
work is needed to delineate the roles these PRR pathways in nonhematopoietic and immune cells 
play in pathogenesis of CHIKV disease. 
  Recently, the laboratory of Tem Morrison demonstrated that monocytes play an important 
role in limiting disease severity and viral dissemination during alphavirus infection72. This study 
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made use of transgenic mice expressing the diphtheria toxin receptor (DTR) under the control of 
CCR2 expression, to allow for specific deletion of CCR2+ cells, namely monocytes. Loss of 
monocytes worsened clinical disease and viral loads following infection with a related alphavirus, 
Ross River virus (RRV). Additionally, they generated CCR2-DTR  DKO BMCs and 
demonstrated that monocytes are the critical immune cell for inducing protective IFN-I. 
Unfortunately, they did not perform these same BMC experiments with CHIKV, but they did 
demonstrate that depletion of monocytes also resulted in more severe clinical disease and viral 
dissemination during CHIVK infection. Other work demonstrated that CHIKV is able to bind and 
enter monocytes and induce IFN-I production, but ultimately yields a nonproductive infection 
(discussed further in section 1.1.6)65. Together these data imply that similar to RRV infection, 
monocytes may be an essential hematopoietic source of IFN-I during CHIKV infection, but more 
work is needed to confirm this. This would be consistent with the observation that both human and 
mouse pDCs stimulated with CHIKV in vitro produced very little IFN-I compared to stimulation 
with poly I:C, an agonist of TLR3, or influenza A, suggesting that another cell type is likely 
responsible for producing IFN-I116. 
1.2.5 IFN-I Action during CHIKV Infection 
IFN-I Signals on Nonhematopoietic Cells 
 Mice that lack IFNAR1, and thus all IFN-I activity, are extremely susceptible to CHIKV 
and other alphavirus infections, indicating that IFN-I are critical host factors for controlling 
CHIKV infection56,64,97,116,118–120. Loss of both IRF3 and IRF7 (DKO) fail to produce sufficient 
IFN-I and die from uncontrolled CHIKV replication and hemorrhagic shock-like symptoms, 
similar to what is observed in IFNAR1 deficient mice64. The kinetics of lethality are slightly 
delayed in the DKO mice compared to the IFNAR1-KO phenotype, suggesting that other factors, 
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such as IRF1 or IRF5, may also induce some IFN-I during CHIKV infection, though insufficient 
to control infection. Another study generated reciprocal WT  IFNAR1-/- and IFNAR1-/-  WT 
BMCs to determine the cell type-dependent IFNAR expression responsible for controlling CHIKV 
infection116. They found that IFN-I signaling is required on nonhematopoietic cells to control 
CHIKV infection. However, the authors did not evaluate pathogenesis or viral load, so there is 
possibility of some involvement of IFN-I signaling on immune cells during CHIKV infection. 
Altogether, these findings are unsurprising given that the cellular targets of CHIKV are primarily 
nonhematopoietic cells, such as fibroblasts and muscle cells. 
Functions of ISGs in CHIKV Infection 
 IFN-I ultimately exert their biological properties by inducing ISGs, but only a short list of 
ISGs have been studied in the context of CHIKV infection. Viperin (encoded by the gene Rsad2) 
was found to restrict CHIKV replication in vitro, and Rsad2-/- mice were more susceptible to 
CHIKV infection121. Protein kinase R (PKR) transcription is regulated by both IFN-I signaling and 
various stress responses, and then it requires activation by the presence of dsRNA. Once active, 
PKR phosphorylates the eukaryotic translation initiation factor (eIF2α) to inhibit cellular mRNA 
translation, but it can also indirectly aid in activation of multiple transcription factors, such as 
STAT1122. Studies have demonstrated that PKR is activated during CHIKV infection in vitro, 
which leads to the upregulation of several genes that promote IFN-I production, such as GADD34. 
Cells lacking PKR or GADD34 supported increased CHIKV replication and induced very little 
IFN-β123,124. Furthermore, neonatal mice lacking GADD34 were more susceptible to CHIKV-
induced lethality compared to WT mice and supported higher viral loads in multiple tissues, 
establishing important anti-CHIKV properties for PKR and GADD34 in vivo. 
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 Additionally, IFITM3 has been demonstrated to block CHIKV fusion in cells, and BST2 
(also known as tetherin) has been shown to block CHIKV budding. Both IFITM3 and BST2 play 
antiviral roles during CHIKV infection in vivo, as mice that lack either IFITM3 or BST2 displayed 
worsened disease and higher viral replication in several tissues125–127. ISG15 is one of the most 
rapidly and abundantly upregulated genes in response to IFN-I. It contains two ubiquitin-like 
domains, and similar to ubiquitin, it can be conjugated to viral and host proteins128. ISG15-KO 
neonatal mice are much more susceptible to CHIKV-induced lethality, but displayed similar viral 
loads throughout infection. Rather than functioning to limit viral replication, as it does in several 
other viral systems, the absence of ISG15 during neonatal CHIKV infection promoted a cytokine 
storm phenotype58. Collectively these studies have begun to define the mechanistic basis for ISG-
mediated modulation of CHIKV replication and pathogenesis, but much work remains characterize 
the roles of ISGs during CHIKV infection. 
 In summary, there has been substantial effort to characterize the pathways and cell types 
that induce IFN-I during CHIKV infection, the cells that respond to IFN-I, and the mechanistic 
actions of some ISGs. This collective work has yielded a model in which IFN-I signaling is 
absolutely required on nonhematopoietic cells to control CHIKV infection. Both hematopoietic 
cells, likely monocytes, and nonhematopoietic cells can produce sufficient IFN-I to control 
CHIKV, though they utilize distinct pathways to do so. Hematopoietic cells likely utilize the 
TLR3-TRIF pathway, whereas nonhematopoietic cells rely on the RIG-I/MDA5-MAVS 
pathways. A central role for nonhematopoietic cells, like fibroblasts and muscle, for supporting 
viral replication and coordinating immune responses sets CHIKV apart from other alphaviruses. 
Related alphaviruses such as RRV, Sindbis virus (SINV), and Venezuelan equine encephalitis 
virus (VEEV), as well as the flavivirus West Nile virus (WNV), are all able to infect and induce 
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IFN-I production in dendritic cells118,129,130. Thus, CHIKV infection could serve as a unique model 
to study IFN-I responses in nonhematopoietic cells. 
1.2.6 IFN-I Subtypes: evidence for functional differences 
 IFN-I are pleiotropic cytokines with broad biological activities that include upregulating 
cell-intrinsic antiviral defense mechanisms, modulating proinflammatory cytokine production, and 
augmenting innate and adaptive cellular responses. Despite signaling through a single, shared 
receptor, the IFN-I subtypes have been documented to have distinct properties both in vitro and in 
vivo. Examples and mechanisms of these functional differences are discussed below. 
Functional differences in vitro 
 All IFN-I subtypes bind to IFNAR, but with varying affinities. For example, IFN-α2 has 
nanomolar binding affinity to IFNAR2 and micromolar affinity for IFNAR1, whereas IFN-β 
exhibits picomolar binding affinity for IFNAR2 and nanomolar affinity for IFNAR1131,132. 
Differences in binding affinities among the IFN subtypes manifest as differences in dissociation 
constants. IFN-β has about a 100 second half-life in a ternary complex with both receptors, and 
IFN-α2 has a half-life of about 1 to 5 seconds133,134. Careful mapping of structural and biochemistry 
properties have revealed that for some IFN-I properties, such as antiproliferative activity, different 
potencies among the subtypes are ascribed to differential binding affinities and dissociation rates 
for the receptor. These properties that are highly dependent on cellular context and affinity are 
designated as “tunable” IFN properties. For example, IFN-β has the highest known natural affinity 
for IFNAR and has been shown to be the most potent inhibitor of osteoclastogenesis of monocytic 
precursors in vitro135. In contrast, “robust” IFN-I properties, such as antiviral activity, only 
marginally improve with increased affinity and are programmed for maximal output by all 
subtypes irrespective of affinity or cellular context136. The ability of IFN-I signaling to have graded 
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responses to multiple ligands likely contributes to the pleiotropic activities ascribed to IFN-I and 
provides a molecular explanation for how IFN-I subtypes can have unique properties (summarized 
in Figure 1.5). 
Lessons from IFN-ε 
 Prior to 2013, the function of IFN-ε remained uncharacterized. A study published in 
Science showed that unlike the other type I IFN subtypes, IFN-ε is not induced by Toll-like 
receptor ligands. Rather, it is constitutively expressed by the epithelium of reproductive organs, 
with its expression further regulated by sex hormones137. Likely a consequence of its unique 
regulation, IFN-ε is the only type I IFN subtype shown to play a protective role against Chlamydia 
infection, whereas the other subtypes may worsen disease137,138. IFN-ε signals through IFNAR like 
the other IFN-I subtypes, but with some notable differences. A recent paper demonstrated that 
unlike other studied IFN-I subtypes, IFN-ε displays higher affinity for the IFNAR1 subunit 
compared to IFNAR2139. Additionally, IFN-ε was the only subtype shown to have cross-species 
reactivity for human IFNAR, which had also been previously shown for canine IFN-ε140. 
Collectively, these studies demonstrate that IFN-ε has distinct biological properties both in vitro 
and in vivo, and these distinctions are relevant for human disease. 
IFN-β deficient mice 
 Some of the first attempts to delineate properties of individual IFN-I subtypes in vivo came 
with the generation of mice that specifically lack the IFN-β subtype141. IFN-β-KO mice are more 
susceptible than wild type (WT) mice to West Nile virus (WNV), an encephalitic flavivirus142. The 
increased lethality in the IFN-β-/- mice was accompanied with elevated viral replication in some, 
but not all tissues. WNV was similarly controlled in the serum and spleen by IFN-β-KO and WT 
mice, and consistent with this, IFN-I activity in the serum was comparable between the two 
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genotypes. Onset of viral replication was similar in certain peripheral tissues, such as the central 
nervous system (brain and spinal cord) and kidneys, but viral loads accumulated to higher levels 
in the IFN-β deficient mice. This suggests that for some tissues, IFN-β functions to limit replication 
within those tissues, but not the viral seeding of those tissues. In striking contrast, the lymph nodes 
displayed very early and severely elevated replication, suggesting an early antiviral role of IFN-β 
in select tissues. Furthermore, WNV infection of cell cultures generated from IFN-β-KO mice 
revealed that macrophages and dendritic cells supported significantly higher WNV replication 
compared to WT cells, whereas the phenotype was minimal or non-existent in cultured fibroblasts 
and neurons, suggesting that there might be cell-type specificity for requirement of certain IFN-I 
subtypes. Taken together, these data suggest that during WNV infection IFN-β has a protective, 
antiviral role in limiting replication in certain cell types and tissues, and of note, the virologic 
phenotype in IFN-β-KO mice was not as severe as what has been described for WNV infection in 
mice lacking other components of the IFN-I system (Ifnar-/-, Irf3-/-, or Irf7-/- mice)96,130,143. 
 Several other studies have also identified a protective, antiviral role for IFN-β during viral 
infection. One study demonstrated that IFN-β-KO mice were more susceptible to 3 different doses 
of intranasal inoculation of vaccinia virus, a member of Poxviridae with a dsDNA genome144. 
Similar to what was observed with WNV infection, only certain tissues displayed increased viral 
loads, namely the lung and brain, but not the spleen. Another study demonstrated a protective role 
for IFN-β in coxsackievirus B3 infection145. Coxsackievirus group B belong to the Picornaviridae 
family of positive-sense, ssRNA viruses that cause viral myocarditis. When infected with 
coxsackievirus B3, 70% of IFN-β-/- mice succumbed to infection by 5 dpi, whereas 100% of WT 
mice survived. Interestingly, the viral loads at 4 dpi (just before lethality) were not different in the 
heart and only slightly elevated in the liver and spleen in the IFN-β-KO mice; however, IFN-β-
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KO mice did show increased inflammation and infiltrates by histology in the heart compared to 
WT mice, suggesting that IFN-β might have protective antiviral and immunomodulatory functions 
in this context. 
 One of the most intriguing and complicated viral systems to study IFN-I biology might be 
influenza A (IAV) infection. Some studies have reported that IFN-I directly correlates with disease 
severity, whereas other studies indicated that IFN-I inversely correlated with pathology146. 
Pretreatment of mice with IFN 8 hours prior to infection protected mice from severe infection, but 
only in mice that expressed the IAV-restricting ISG MX1147. In contrast, treatment of MX1-
negative mice with exogenous IFN-I increased morbidity and mortality during IAV infection by 
upregulation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)148. These 
findings highlight that during IAV infection, IFN-I have a complex role, and whether they play a 
beneficial or detrimental role may depend on the genetic background of the mouse, dose or route 
of the inoculum, and concentration of IFN-I induced. C57BL/6 mice are MX1-negative and 
susceptible to influenza infection. One study generated C57BL/6 mice that do express MX1 but 
are deficient for IFN-β149. In this MX1-postive genetic background, IFN-β was shown to play a 
protective antiviral role, as mice lacking IFN-β showed greater lethality and higher viral burden in 
the lung following IAV infection. Taken altogether, the current model of IFN-I activity during 
IAV infection is that moderate, transient expression of IFN-I induces a protective antiviral 
response, whereas excessive or prolonged IFN-I induction is detrimental by exacerbating 
inflammation. 
IFN-α versus IFN-β during LCMV Infection 
 The lack of IFN-α deficient mice has hindered the direct functional comparison of IFN-α 
versus IFN-β in vivo, but the recent development of blocking monoclonal antibodies (mAb) 
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specific for either IFN-α or IFN-β is making those studies possible98. In a study with lymphocytic 
choriomeningitis virus (LCMV) persistent infection (clone 13), Oldstone and colleagues 
demonstrated that IFN-β is dispensable for controlling early LCMV replication and spread, 
suggesting that other subtypes, such as the IFN-α’s, are the dominant subtypes contributing to the 
antiviral responses. Indeed, blockade of IFN-α worsened viral loads. In contrast, IFN-β was found 
to be detrimental to the host and responsible for promoting LCMV persistence150. Specific 
blockade of IFN-β improved antiviral T cell responses that led to accelerated virus clearance, 
recapitulating what is observed with blockade of IFNAR1 during LCMV infection151,152. Infection 
of dendritic cells is an important step for establishment of persistent LCMV infection, and mice 
that were treated with anti-IFNAR1 or anti-IFN-β mAb showed decreased infection of CD8α– 
dendritic cells, suggesting a mechanism for viral clearance. Whereas studies have been performed 
to assess the specific role of the IFN-β subtype, this was the first report to directly compare the 
properties of IFN-α and FIN-β and observe distinguishable biological functions. 
 Collectively, these studies highlight that cellular source, timing, concentration, and context 
of expression can drastically impact the function of an IFN-I subtype. IFN-I are both the targets of 
and used as therapeutics for a number of diseases, such as hepatitis C infection, multiple sclerosis, 
and some cancers, and careful study of the functions of individual subtypes may lead to more 
effective treatments with less off-target effects153. 
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1.3 Figures 
 
Figure 1.1 Replication cycle of CHIKV in mammalian cells 
This figure was taken from Silva, L. A. & Dermody, T. S. Chikungunya virus: epidemiology, replication, 
disease mechanisms, and prospective intervention strategies. J. Clin. Invest. 127, 737–749 (2017). In brief, 
CHIKV replication in mammalian cells is characterized by i-iii) receptor-mediated endocytosis and pH-
dependent fusion, iv-v) early replication of negative-strand genome occurs in spherules, vi-viii) formation 
of large cytopathic vacuoles (CPV-I) where subgenomic and genomic RNA are transcribed and translated, 
resulting in accumulation of nucleocapsids and E1/E2 dimers at the cell surface, and x-xi) nucleocapsids 
associate with internalized E1/E2 spikes (CPV-II) to form mature virions, which egress and bud from the 
cell. 
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Figure 1.2 Summary of CHIKV pathogenesis in WT mice 
This figure was taken from Fox, J. M. & Diamond, M. S. Immune-Mediated Protection and Pathogenesis 
of Chikungunya Virus. J. Immunol. 197, 4210–4218 (2016). Infection of WT mice with CHIKV in the foot 
produces a biphasic swelling response that is accompanied with histological signs of arthritis, myositis, and 
synovitis. The first peak of foot swelling at 2-3 dpi is thought to arise from robust viral replication which 
drives cell death, local proinflammatory cytokine production, and edema (box 1). The second peak at 6-7 
dpi occurs as infectious virus is cleared from the tissues and blood and is associated with an influx of 
inflammatory infiltrates into the joint spaces and surrounding soft tissues that drive cytokine production, 
synovitis, myositis, and edema (box 2). 
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Figure 1.3 Summary of pathways of IFN-I induction and signaling 
This figure was taken from McNab, F., Mayer-Barber, K., Sher, A., Wack, A. & O’Garra, A. Type I 
interferons in infectious disease. Nat. Rev. Immunol. 15, 87–103 (2015). Briefly, pattern recognition 
receptor signaling pathways converge on the activation of IRF3 and/or IRF7 to induce IFN-I production. 
IFN-I then exert pleiotropic effects by signaling through IFNAR to induce various JAK/STAT signaling 
pathways and IFN-stimulated genes (ISGs). IFN-I can also activate other pathways, such as PI3K and 
MAPKs. 
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Figure 1.4 IRF7 participates in a forward feedback loop for IFN-I amplification 
This figure was taken from Honda, K. & Taniguchi, T. IRFs: master regulators of signalling by Toll-like 
receptors and cytosolic pattern-recognition receptors. Nat. Rev. Immunol. 6, 644–658 (2006). In the early 
phase of IFN-I induction, IRF3 (or IRF7 in some cells, such as pDCs) acts on the promoter of IFN-β (and 
IFN-α4, not depicted). Secreted IFN-I signals through IFNAR to upregulate IRF7, which can then bind the 
promoters of the other IFN-α subtupes, as well as IFN-β, to amplify the IFN-I response. 
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Figure 1.5 Molecular basis for functional differences among IFN-I subtypes 
This figure was taken from Schreiber, G. & Piehler, J. The molecular basis for functional plasticity in type 
I interferon signaling. Trends Immunol. 36, 139–149 (2015). Upper panel: The affinities (KD) for each 
receptor subunit and EC50 values for antiviral and antiproliferative activities are listed for three natural IFN-
I subtypes (IFN-α1, IFN-α2, and IFN-β) and two engineered IFN-α mutants (YNS and IFN-1ant). Lower 
panel: Some IFN-I properties are “robust” and do not correlate with affiinty to the receptor, whereas 
“tunable” IFN-I properties require longer or continuous activation of the receptor, display a linear 
correlation with affinity for the receptor, and may be cell type specific. 
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Chapter 2 
Interferons alpha and beta protect against chikungunya 
virus pathogenesis by distinct mechanisms of action 
 
 
This chapter contains data from a manuscript in preparation for submission. 
L. E. Cook, M. C. Locke, A. R. Young, K. Monte, M. L. Hedberg, R. M. Shimak, D. J. Veiss, 
M. S. Diamond, D. J. Lenschow. Interferon alpha limits chikungunya virus replication, but not 
interferon beta, which controls immunopathology mediated by neutrophils. (2018). 
  
35 
2.1 Abstract 
 Type I interferons (IFN-I) possess a wide range of biological activity and are important in 
protection against a number of viruses, including alphaviruses. Despite signaling through a shared 
receptor, there are well documented biochemical and functional differences among the different 
IFN-I subtypes. Work with lymphocytic choriomeningitis virus (LCMV) persistent infection 
previously demonstrated that IFN-α and IFN-β have distinguishable biological activities, with 
IFN-α functioning to limit viral replication and IFN-β playing a detrimental role by promoting 
persistent infection. Herein, we demonstrate that IFN-α and IFN-β both play protective roles 
during acute CHIKV infection, but they do so by distinct mechanisms. IFN-α limits CHIKV 
replication and dissemination, but in contrast, IFN-β protects from CHIKV pathogenesis by 
limiting immunopathology mediated by neutrophils. Our findings support the accumulating 
evidence that the IFN-I subtypes have distinct biological activities, and we identify a novel 
mechanism for the differential activity of IFN-β compared to the IFN-α’s. 
2.2 Introduction 
 Type I interferons (IFN-I) are a family of multifunctional cytokines, and in mice they 
consist of 14 IFN-α subtypes and single forms of IFN-β, IFN-ε, IFN-κ, and IFN-ω. Their broad 
pleiotropic properties include upregulating cell-intrinsic antiviral defense mechanisms, 
modulating proinflammatory cytokine production, and augmenting innate and adaptive cellular 
responses. All IFN-I exert their effects by binding to the shared heterodimeric IFN-α/β receptor 
(IFNAR), which is composed of the subunits IFNAR1 and IFNAR2. Engaging IFNAR activates 
Janus kinase (JAK) and signal transducer and activator of transcription (STAT) signaling programs 
to modulate the expression of hundreds of interferon stimulated genes (ISGs)104. Conservation of 
36 
the IFN-I family’s multigene nature across many species suggests that expression of multiple IFN 
subtypes is beneficial for the host defense. However, the physiological roles of the individual 
subtypes remain poorly understood. 
 IFN-I are rapidly induced in response to infection with viruses and other pathogens. Host 
pattern recognition receptors (PRR) that recognize nucleic acids are important sensors of viral 
infection. For many cells, the immediate response to PRR signaling leads to the production of IFN-
β and IFN-α4 subtypes via activation of interferon regulatory factor 3 (IRF3). These initial IFN-I 
subtypes signal in autocrine and paracrine means to modulate expression of ISGs that include 
antiviral effector and regulator molecules. IRF7 is among the transcriptional regulators induced by 
the early IFN-I subtypes, and it participates in a positive feedback loop that induces the other IFN-
α subtypes, thus amplifying and diversifying the IFN-I response85,94,95. The central role of IRF7 in 
inducing the IFN-α subtypes is demonstrated in IRF7 deficient mice, which fail to produce many 
of the IFN-α subtypes in response to viral infection64,96–98. 
 Despite possessing a similar spectrum of activities, the IFN-I subtypes display unique 
properties and different potencies of shared functions. Structural and biochemistry studies have 
ascribed these distinct properties to differential binding affinities and dissociation rates for the 
IFN-I receptor154–157. The ability of IFNAR to have graded responses to multiple ligands likely 
contributes to the wide range of biological activity documented for IFN-I, but until recently, the 
physiological relevance of these biochemical differences was unclear. In a study with lymphocytic 
choriomeningitis virus (LCMV) persistent infection, Oldstone and colleagues demonstrated that 
IFN-β is dispensable for controlling LCMV replication and spread, suggesting that other subtypes, 
such as the IFN-α’s, are the dominant subtypes contributing to the antiviral response. Instead, IFN-
β was found to be detrimental to the host and responsible for promoting LCMV persistence. 
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Specific blockade of IFN-β improved antiviral T cell responses that lead to accelerated virus 
clearance, recapitulating what is observed with blockade of IFNAR1 during LCMV infection150–
152. Infection of dendritic cells is an important step for establishment of persistent LCMV infection, 
and mice that were treated with anti-IFNAR or anti-IFN-β mAb showed decreased infection of 
CD8α– dendritic cells, suggesting a mechanism for viral clearance. Taken together, the 
biochemical evidence and work with LCMV demonstrate that IFN-α’s and IFN-β have 
distinguishable biological activities and that these differences can have profound implications for 
viral pathogenesis. 
 Chikungunya virus (CHIKV) is a mosquito-transmitted alphavirus capable of causing 
explosive outbreaks of acute fever, rash, polyarthritis, arthralgia, and myositis2,8. These symptoms 
reflect an interplay between extensive viral replication and damage mediated by immune cells, 
such as macrophages and activated CD4+ T cells51,53,79. However, not all immune responses are 
detrimental. Neutralizing antibodies and IFN-I have been shown to be important in controlling 
CHIKV infection, and mice that lack IFNAR rapidly succumb to infection due to hemorrhagic 
shock and uncontrolled virus dissemination17,64. Despite their central role in limiting alphavirus 
infection, little is known about the contributions of individual IFN-I subtypes to protection against 
CHIKV infection. To explore this question we used genetic deletion mutants and antibody 
blockade to determine the contributions of IFN-α and IFN-β during acute CHIKV infection. Both 
IFN-α and IFN-β protect the host during acute CHIKV infection. However, our findings suggest 
distinct roles for the IFN-I subtypes during CHIKV infection, with IFN-α limiting early viral 
replication and spread and IFN-β controlling neutrophil-mediated immunopathology. Thus, these 
results define a novel mechanism by which IFN-β can have distinguishable biological activity from 
the IFN-α’s.  
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2.3 Results 
 IFN-α and IFN-β both play protective roles in limiting clinical CHIKV disease. Human 
patients and mice infected with CHIKV mount a robust innate immune response, including the 
induction of IFN-I and other cytokines and chemokines56,58. Loss of IFNAR1 in mice leads to 
uncontrolled viral replication and dissemination, with mice succumbing to infection by 3-4 days 
post infection (dpi) from hemorrhagic shock-like symptoms56,58,64. Evidence shows that the IFN-I 
subtypes have distinct biological properties, but there have been no studies performed to determine 
the roles of individual subtypes in CHIKV pathogenesis. 
 To address this, we evaluated the pathogenesis of CHIKV in wild type C57BL/6J (WT), 
IFN-β knockout (KO), and IRF7-KO mice. IRF7-KO mice have previously been shown to lose 
IFN-α amplification during CHIKV infection with minimal impact on IFN-β production64. 
Animals were infected subcutaneously in the left rear foot with 103 plaque forming units (PFU) of 
a clinical isolate of CHIKV (La Réunion, 2006) and monitored daily for clinical foot swelling. 
Previous studies have described a biphasic swelling response in the CHIKV-infected foot of WT 
mice, with a first peak usually observed 2-3 dpi and a second, larger peak at 6-7 dpi. Mice that 
lack IFN-β developed much more severe foot swelling that mimics the kinetics of swelling seen 
in WT mice (Fig. 2.1A, p < 0.0001). In contrast, mice that lack IRF7 develop a large initial peak 
of swelling at 3 dpi and a delayed second peak at 11 dpi (Fig. 2.1A, p < 0.0001). Both IFN-β-KO 
and IRF7-KO mice also displayed prolonged foot swelling out to at least 15 dpi compared to WT 
mice, which typically clear swelling by about 12 dpi (Fig. 2.1A). These data highlight that IFN-β 
and IFN-α both play important protective roles to limit clinical disease during CHIKV infection, 
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but the differences in the kinetics of swelling between the IFN-β-KO and IRF7-KO mice suggest 
that different mechanisms may underlie these phenotypes. 
 Though IRF7 has previously been shown to play a critical role in IFN-α production, it is 
also known to regulate a number of antiviral genes independent of IFN production, for example 
tetherin (also known as BST-2 or CD317)158. Therefore, to evaluate if the phenotype in IRF7 
deficient mice was due to loss of IFN-α, we made use of a pan-IFN-α blocking antibody (TIF-
3C5) and an IFN-β specific blocking antibody (HDβ-4A7) to more directly assess the impact of 
the IFN subtypes on CHIKV pathogenesis98,150. WT mice were treated with the blocking antibodies 
one day before and again one day after CHIKV infection and monitored for foot swelling in the 
ipsilateral foot. Monoclonal antibody (mAb) blockade of IFN-α or IFN-β mimicked the early 
swelling trends observed in the IRF7 and IFN-β deficient mice, respectively. At 3 dpi, both the 
IFN-α and IFN-β mAb blockade groups displayed an increase in foot swelling compared to the 
isotype control treated group (Fig. 2.1B, p < 0.0001). However, the foot swelling at later acute 
time points (7-14 dpi) in the IFN-I blockade groups were less severe than the genetic deletion 
models, which could be due to the limited dosing regimen or partial blockade. These data confirm 
that the early foot swelling phenotypes in IFN-β-KO and IRF7-KO mice are due to loss of IFN-β 
and IFN-α, respectively. Taken together, these results suggest that IFN-β and IFN-α have distinct, 
non-redundant roles in protection from CHIKV clinical disease. 
 IFN-β-KO, but not IRF7-KO, mice have increased cellular infiltration into the 
midfoot joint spaces during acute CHIKV infection. In a WT mouse, the first peak of foot 
swelling (2-3 dpi) is thought to arise from robust viral replication which drives cell death, local 
proinflammatory cytokine production, and edema. The second peak (6-7 dpi) occurs as infectious 
virus is cleared from the tissues and blood and is associated with an influx of inflammatory 
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infiltrates into the joint spaces and surrounding soft tissues that drive cytokine production, 
synovitis, myositis, and edema51,53,55,79. To determine if the increased foot swelling observed with 
loss of IFN-α or IFN-β was associated with worsened arthritis and inflammation, we next evaluated 
histological sections for overall inflammation of the joints and musculoskeletal tissues in the 
ipsilateral foot of WT, IFN-β-KO, and IRF7-KO mice at 7 dpi infection in a blinded manner. We 
found that 100% of the IFN-β-KO mice showed severe inflammation (score of 3) in the infected 
foot, whereas there was more variability in the severity of inflammation in the WT and IRF7-KO 
mice (Fig 2.2A and 2.2C). Additionally, IFN-β-KO mice, but not IRF7-KO mice, showed 
increased cellular infiltration into the midfoot joint spaces at 7 dpi compared to WT mice (Fig. 
2.2D, p < 0.01). These data demonstrate that while both IFN-β-KO and IRF7-KO mice develop 
severe CHIKV-induced foot swelling, only the IFN-β-KO mice appear to show increased 
pathology, especially as measured by cellular infiltration into the mid-foot joint spaces. 
 IFN-α, but not IFN-β, limits CHIKV replication and dissemination. To further 
investigate the differential roles of IFN-α and IFN-β, we next determined the infectious viral load 
in the ipsilateral foot and distal tissues at varies times post infection by plaque assay. Analysis of 
the ipsilateral foot revealed that mice lacking IFN-β supported CHIKV replication at similar levels 
as WT mice (Fig. 2.3A). Clearance of infectious virus was similar between WT and IFN-β-KO 
mice, with detectable virus cleared from both strains by 10 dpi (Fig. 2.3A). In contrast, mice 
lacking IRF7 had 1 log10 higher CHIKV viral load in the ipsilateral foot at 2 and 3 dpi compared 
to WT mice (Fig. 2.3A, p < 0.01) and had delayed clearance of infectious virus compared to WT 
or IFN-β-KO mice, with 2 log10 more infectious virus at 7 dpi (Fig. 2.3A, p < 0.001). 
 We next evaluated the impact of loss of IFN-β or IRF7 on CHIKV dissemination to distant 
tissues. Overall, we observed minimal difference between WT and IFN-β-KO mice in viral titers 
41 
in several disseminated tissues. CHIKV titers in the serum of IFN-β-KO mice were the same as 
WT mice at all time points examined. Likewise, we observed no difference in the time of onset of 
replication in the distant tissues of IFN-β-KO mice, and only in the muscle did we observe a 
significant change in the overall magnitude of viral replication compared to WT mice at 3 dpi (Fig. 
2.3A, p < 0.0001). Conversely, IRF7-KO mice displayed a substantial increase in CHIKV 
dissemination. IRF7-KO mice had substantially higher and prolonged viremia compared to WT 
and IFN-β-KO mice, with 2 log10 more virus at 2 dpi and a 5 log10 increase at 3 dpi in the serum 
(Fig. 2.3A, p < 0.0001). Additionally, CHIKV spread to distant sites much more quickly and 
sustained elevated viral loads in IRF7-KO mice compared to WT mice. For example, IRF7-KO 
contralateral ankles rapidly develop a 3 log10 increase in replication at 2 dpi, at a time when 
replication is only just detectable in WT and IFN-β-KO mice. Additionally, whereas IFN-β-KO 
and WT mice have cleared CHIKV from the opposite ankle at 7 dpi, there is still 104.5 pfu of virus 
present in the IRF7-KO mice. These data suggest that IFN-β is dispensable for controlling CHIKV 
replication and spread, and that other IFN-I subtypes, such as the IFN-α’s, are the dominant 
subtypes eliciting antiviral responses. 
 Administering mAb blockade of either pan-IFN-α or IFN-β recapitulated the virologic 
phenotypes we observed in the genetic knockout models. Blockade of IFN-β in WT mice had 
minimal impact on viral load in the ipsilateral foot or in distal sites compared to mice treated with 
an isotype control mAb (Fig. 2.3B). Treatment of WT mice with the IFN-α blocking mAb resulted 
in an elevated viral load in the inoculated ankle at 7 dpi, more severe viremia, and a substantial 
increase in dissemination to the muscle and distal joints, similar to what we observed in IRF7 
deficient mice (Fig. 2.3B). These data suggest that IFN-α is important for controlling early viral 
replication and spread, whereas IFN-β is dispensable for these effects. In contrast, the absence of 
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IFN-β led to increased foot swelling and increased inflammatory cell infiltrates into the joint 
spaces without impacting viral loads, suggesting that IFN-β may primarily function as an 
immunomodulatory molecule during CHIKV. Taken together, these findings demonstrate that 
IFN-α and IFN-β are both protective during CHIKV infection but mediate their effects by distinct 
mechanisms of actions. 
 IFN-α and IFN-β exert their protective effects during CHIKV arthritis by signaling 
on nonhematopoietic cells. Previous studies using bone marrow chimeras have demonstrated that 
IFN signaling is required in nonhematopoietic cells to survive CHIKV infection116. However, these 
studies evaluated only survival and did not determine the impact of IFN-I signaling on 
immunopathology in the CHIKV arthritis model. To address this question, we utilized Vav-Cre 
transgenic mice crossed onto the IFNAR1flox/flox background, which removes IFN-I signaling from 
immune cells and endothelial cells159. Infecting Vav-Cre positive mice with 103 pfu CHIKV in the 
footpad resulted in no lethality and did not yield any significant difference in clinical disease, as 
measured by foot swelling, compared to Cre negative littermate controls (Fig. 2.4A). To determine 
if loss of IFN-I signaling in hematopoietic cells impacts the ability to control viral replication or 
spread, we assessed the viral load in the ipsilateral foot and distant tissues at several times post 
infection. We did not observe significant differences in viral replication in the ipsilateral ankle or 
distant tissues, though there was a slight delay in clearance of CHIKV from the serum (Fig. 2.4B, 
p < 0.05). Taken together, these data suggest that IFN-α and IFN-β mainly signal on 
nonhematopoietic cells to exert their respective protective effects during CHIKV arthritis. 
 IFN-β deficient mice have increased neutrophil recruitment into the ipsilateral foot 
during CHIKV infection. Mice lacking IFN-β begin to develop increased foot swelling by 2 dpi, 
but tissues support a similar level of CHIKV replication (Fig. 2.1-2.3). This led us to hypothesize 
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that IFN-β protects from CHIKV pathogenesis by modulating the innate immune response. 
Therefore, we first sought to determine how the absence of IFN-β affected early (2-3 dpi) cellular 
recruitment into the ipsilateral foot tissue. Previous studies have demonstrated that macrophages, 
monocytes, and neutrophils are among the early cells recruited to the infected foot and that altering 
the balance of these infiltrating cells can drastically impact disease51,52,71,72. To quantitate 
differences in immune cell infiltration into the foot, infected WT or IFN-β-KO mice were 
sacrificed at 2 or 3 dpi, and the infected foot was disarticulated and digested to generate a single 
cell suspension23. We stained the cell suspension for various surface cell identifying markers and 
analyzed the cells were analyze by flow cytometry to determine the total number of immune cells 
(CD45+), inflammatory monocytes (Ly6C+ CD11b+ Ly6G-), neutrophils (Ly6G+ CD11b+), and 
macrophages (F4/80+ MERTK+) (fig. S2.1). At 2 dpi, we observed an increase in the total number 
of neutrophils (4-fold), as well as a significant increase in the percentage of neutrophils among 
CD45+ immune cells in mice lacking IFN-β compared to WT mice (Figure 2.5A, p < 0.05 and p < 
0.0001). By 3 dpi, there was no longer a difference in neutrophil number, though there was still an 
increase in percentage of neutrophils at this time point (Fig. 2.5A, p < 0.0001). We did not observe 
a difference in total number of CD45+ cells, monocytes, or macrophages between WT and IFN-β 
KO mice, but we did see a minor decrease in the percentage of monocytes at 2 dpi (Fig. 2.5A, p < 
0.05). Consistent with the histological observations, these results suggest that IFN-β functions to 
limit immunopathology during CHIKV infection by modulating neutrophil infiltration into the 
ipsilateral foot. 
 Mice lacking IFN-β have increased early IL-9 levels in the ipsilateral foot. We next 
assessed local cytokine and chemokine levels to determine the basis for increased neutrophil 
recruitment in the infected feet of IFN-β-KO mice. Using a multiplexed assay, we measured 
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cytokine and chemokine levels in the ipsilateral foot at 2 and 3 dpi in WT and IFN-β-KO animals. 
We did not observe elevated proinflammatory cytokines, such as IL-6, IL-1β, or TNF-α, or 
common neutrophil chemoattractants, such as CXCL1 (KC) or CXCL2 (MIP-2) in the IFN-β-KO 
mice. In a panel of 25 cytokines and chemokines the only analyte significantly elevated in IFN-β-
KO foot tissue was IL-9 at 2 dpi (Fig. 2.6, p < 0.0001). Previous studies have shown that IL-9 can 
contribute to acute inflammation in certain models including rheumatoid arthritis160. Importantly, 
IL-9 has been linked to neutrophil survival and function in a model of arthritis, and furthermore, 
in the context of experimental autoimmune uveoretinitis (EAU), treatment with IFN-β inhibited 
IL-9 production by splenocytes161,162. Thus, elevated IL-9 points to a potential mechanism for 
increased neutrophil numbers present in the IFN-β-KO mice. 
 Depletion of neutrophils alleviates the increased foot swelling seen in CHIKV-infected 
IFN-β-KO mice, but not in IRF7-KO mice. Because we observed an increase in number and 
percentage of infiltrating neutrophils in the infected foot of IFN-β KO mice at 2 and 3 dpi, which 
correlates with when we first begin to see differences in clinical disease, we sought to determine 
if neutrophils are responsible for the increased clinical disease severity in the IFN-β KO. We 
depleted neutrophils by intraperitoneal administration of anti-Ly6G mAb (clone 1A8) one day 
before infection and every other day through 7 dpi in WT, IFN-β-KO, and IRF7-KO mice. 
Neutrophil depletion was confirmed by flow cytometric analysis of the blood 6 or 8 dpi (data not 
shown). Neutrophil depletion had no effect on foot swelling in WT or IRF7-KO mice, but it 
alleviated the increased foot swelling observed in the IFN-β-KO mice to WT levels. The beneficial 
effects of neutrophil depletion began at 2 dpi in the IFN-β-KO mice (Fig. 2.7, p < 0.01), and this 
protective effect persisted throughout the course of acute infection. Importantly, neutrophil 
depletion had no effect on foot swelling in IRF7-KO mice, highlighting that distinct mechanisms 
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are driving pathology in IFN-β-KO versus IRF7-KO mice (Fig. 2.7). This observation 
demonstrates that neutrophils are required for exacerbated CHIKV clinical disease in the IFN-β 
deficient mice. 
2.4 Discussion 
 IFN-I signaling is critical for the protection against a number of RNA and DNA viruses. 
Most of what is known about IFN-I biology comes from in vitro studies or the use of animals that 
lack all IFN-I signaling through IFNAR1 deletion. Neither of these approaches have allowed 
delineation of the roles of individual IFN-I subtypes in physiological context. Recent work with 
lymphocytic choriomeningitis virus (LCMV) persistent infection demonstrated that IFN-α and 
IFN-β have unique and distinguishable biologic functions, with IFN-β being mainly responsible 
for promoting viral persistence150. Blockade of IFN-β during LCMV infection improved antiviral 
T cell responses and ultimately decreased infection of CD8α– dendritic cells (DCs) at later time 
points. In this study we show that both IFN-α and IFN-β play distinct protective roles during acute 
CHIKV infection. We demonstrate that the IFN-α subtypes are sufficient for limiting viral CHIKV 
replication and spread, whereas IFN-β is dispensable for controlling viral replication and instead 
primarily functions to limit immunopathology by an apparent novel mechanism. 
 We demonstrate that the loss of IFN-α by mAb blockade or deletion of IRF7 increased 
CHIKV replication and dissemination to distant tissues, supporting an important antiviral role for 
the IFN-α’s during CHIKV infection. Previous work showed that during LCMV infection 
blockade of IFN-α led to increased viral loads late in infection150. Similarly, IRF7-KO mice 
infected with West Nile virus (WNV), an encephalitic flavivirus also transmitted my mosquitoes, 
showed increased lethality compared to WT mice, and increased susceptibility was associated with 
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lowered IFN-α induction and severe viral dissemination96,98. WNV and Dengue virus (DENV), 
another encephalitic flavivirus, both require IFN-I signaling on hematopoietic cells to control 
infection130,163; however, our findings demonstrate that the antiviral effects of the IFN-α’s during 
CHIKV infection are primarily through their action on nonhematopoietic cells (Fig. 2.4). This is 
supported by previous bone marrow chimera studies that demonstrated that IFN signaling is 
required in nonhematopoietic cells to survive CHIKV infection116. Detailed characterization of 
CHIKV tropism in Ifnar1-/- mice compared to WT mice in the arthritis model has not been done; 
however, IRF3/IRF7 double KO (DKO) mice, which closely resemble the phenotype of IFNAR1-
KO mice during CHIKV infection, have been evaluated. DKO mice showed increased CHIKV 
RNA staining of many similar cell types as WT mice in the ipsilateral foot, but also showed spread 
to the epidermis, presumably due to infection of keratinocytes, which was not observed in WT 
mice64. This is in contrast with what has been observed with loss of IFN-I during other alphavirus 
infections. IFANR1 deletion during infection with a related alphavirus, Sindbis virus (SINV), 
permitted infection of macrophage-DC-like cells, which normally restrict SINV infection in WT 
mice118. Furthermore, related alphaviruses Ross River virus (RRV), SINV, and Venezuelan equine 
encephalitis virus (VEEV) are all able to infect and induce IFN-I production in DCs, whereas this 
has not been observed for CHIKV61,118,129,130. The reason for these differences is not fully 
understood, but it may depend on the receptors or co-receptors for CHIKV entry, which still have 
not been identified. So while IFN-I, particularly the IFN-α’s, appear to play important antiviral 
roles in multiple viral infections, the cell types involved in these protective pathways are different 
depending on the context.  
 Nonhematopoietic cells that are likely important for CHIKV pathogenesis include synovial 
and skin fibroblasts and various muscle cell types, which have all been shown to support robust 
47 
CHIKV replication56,61,64. There have been surprisingly few studies performed to determine how 
these cell types contribute to CHIKV pathogenesis. There is accumulating evidence that stromal 
cells participate in coordinating immune responses during various disease states, such as 
rheumatoid arthritis (RA)164. Synovial fibroblasts are the main stromal cells of the synovium, and 
they are responsible for producing the extracellular matrix (ECM) component of synovial fluid 
and maintaining lubrication of the joint. Cultured human fibroblast-like synoviocytes from RA 
patients were shown to express TLR3, TLR7, RIG-I, and MDA5, and consequently, stimulation 
with polyinosinic-polycytidylic acid (poly I:C) induced IRF3 activation and IFN-I production165. 
CHIKV can infect myoblasts, and certain strains, including La Réunion, are able to infect 
myofibers7. Muscle cells are able to participate in innate immune responses, as IL-1β was shown 
to induce nitric oxide synthase 2 (NOS2 or iNOS) in rat skeletal myoblasts, and human skeletal 
muscle biopsies showed a linear correlation between IL-1β levels and iNOS expression166. 
Keratinocytes are infected by many arboviruses, including WNV and DENV167,168; however, 
human keratinocytes are refractory to CHIKV infection at a post-fusion step but are still able to 
produce cytokines and IFN-I following CHIKV exposure, suggesting that they also might be an 
important contributor to inflammation during CHIKV infection62. Extensive in vitro work has 
demonstrated that different cell types can differentially respond to IFN-I signaling157. Clearly, 
nonhematopoietic cells represent important responders to IFN-I during CHIKV infection in vivo, 
and much more work is needed to characterize the cell type-specific protective antiviral ISGs and 
proinflammatory pathways that are induced in these cells in response to CHIKV infection and IFN-
I signaling. 
 Whereas IFN-α was important for limiting viral replication, we demonstrate that loss of 
IFN-β exacerbates acute CHIKV disease but without having much impact on viral loads at the site 
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of inoculation or in distant tissues, suggesting that IFN-β primarily functions as a beneficial 
immunomodulatory molecule. This is distinct from what was observed with LCMV infection, 
where IFN-β was also dispensable for controlling viral replication but ultimately played a 
detrimental role for the host and promoted LCMV persistence150. In that study, specific blockade 
of IFN-β improved antiviral T cell responses and led to accelerated virus clearance, presumably 
through decreased infection of CD8α– dendritic cells, suggesting that IFN-β likely signals on 
DCs150,169. Additionally, IFN-β has well described beneficial immunomodulatory activity in the 
treatment of multiple sclerosis and its mouse model, experimental autoimmune encephalomyelitis 
(EAE), and in that context, IFN-I signaling was required in myeloid cells to exert protective effects 
and limit autoimmunity170,171. In contrast, we demonstrate that IFN-β is protective in CHIKV 
infection by signaling on nonhematopoietic cells and ultimately limits neutrophil recruitment into 
the site of inflammation (Fig. 2.4 and 2.5). Furthermore, depletion of neutrophils completely 
reversed the exacerbation of clinical CHIKV disease seen in the IFN-β-KO mice. Dysregulated 
neutrophil recruitment has been previously documented to increase acute CHIKV disease severity. 
Mice deficient for the chemokine (C-C motif) receptor 2 (CCR2) or Toll-like receptor 3 (TLR3) 
both developed more severe and prolonged CHIKV arthritis associated with early and severe 
neutrophil infiltration71,117. Increased neutrophil recruitment in the CCR2-KO mice was 
accompanied with increased expression of inflammatory mediators.  However, we were surprised 
to see unaltered, or even slightly lowered, levels of many proinflammatory cytokines and 
chemokines in the ipsilateral foot tissue of IFN-β-KO mice, including the known neutrophil-
attracting chemokines CXCL1 (KC) and CXCL2 (MIP-2α)71. Unexpectedly, IL-9 was the only 
significantly altered cytokine out of 25 tested analytes by multiplex assay (Fig. 2.6). More work 
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needs to be done to determine if IL-9 is directly involved in the worsened CHIKV disease of IFN-
β-KO mice. 
 IL-9 is generally described as a type 2 immunity cytokine, and as such, it has a protective 
role during helminth infections; however, it has also been shown to contribute to pathogenesis 
during autoimmune inflammation, such as rheumatoid arthritis and allergic responses160,172. 
Despite being originally characterized as a T cell cytokine, an IL-9 fate reporter mouse revealed 
that type 2 innate lymphoid cells (ILC2s) are the predominant source of IL-9 during a lung 
inflammation model173. We observed elevated IL-9 prior to the generation adaptive immune 
responses (2 dpi), which suggests that ILC2s are a potential source of IL-9 in the IFN-β-KO mice. 
ILC2s are known to produce IL-9 when they are stimulated with IL-25, IL-33, and thymic stromal 
lymphopoietin (TSLP), which are typically secreted by damaged epithelium barriers174. Synovial 
fibroblasts isolated from RA patients have been shown to produce both IL-33 and TSLP175,176. 
Unfortunately, these cytokines were not in our multiplex panel, but future studies will determine 
if IL-33, IL-25, and TSLP are also dysregulated in IFN-β-KO mice during acute CHIKV infection. 
Previous work in a mouse model of experimental autoimmune uveoretinitis (EAU) showed that in 
vivo IFN-β treatment dampened IL-9 production by ex vivo stimulated splenocytes by an unknown 
mechanism, suggesting that IFN-β may indirectly regulate ILC2 responses in multiple biological 
contexts162. Altogether, our findings suggest a model in which IFN-β signals on synovial cells or 
other nonhematopoietic cells in the foot tissue to modulate IL-9 induction, presumably by ILC2s, 
during acute CHIKV infection. ILC2s have not been evaluated during CHIKV infection, but our 
findings suggest that evaluating the contribution of ILC2s and IL-9 in acute CHIKV pathogenesis 
may reveal important interactions between nonhematopoietic cells and innate immune responses. 
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 The current model of IFN-I-mediated protection during CHIKV infection is that IFN-I 
signaling is absolutely required in nonhematopoietic cells to control and survive infection, yet how 
these different cell types respond to IFN-I and CHIKV infection is poorly understood97,116. IFN-I 
signaling is incredibly complex, and the functional outcome depends on many factors, including 
concentration, IFN-I subtype affinity and half-life with the receptor, IFNAR surface levels, and 
the cell type and biological context. Our studies add to the accumulating evidence that IFN-I 
subtypes have distinct properties in vivo and that even the mechanisms underlying the differential 
functions can vary depending on the biological context. Similar to other systems, we found that 
the IFN-α’s are sufficient to control CHIKV replication and dissemination. In contrast, IFN-β 
functioned to modulate the host immune response by a novel mechanism to protect against 
neutrophil-mediated immunopathology during acute CHIKV infection. There are a number of 
therapeutic agents approved for a variety of diseases that either target or augment the IFN-I 
pathway. Our studies highlight that careful delineation of the biological activities of the IFN-I 
subtypes may lead to more efficacious therapies with less off-target effects and also help explain 
why the multigene nature of IFN-I is conserved across many species. 
2.5 Materials and Methods 
Mice 
 All animal experiments were performed in accordance and with approval of Washington 
University Institutional Animal Care and Use Committee guidelines, and all mouse infection 
studies were performed in an animal biosafety level 3 laboratory. All experiments were performed 
with 4-week-old male mice. C57BL/6J (WT), interferon beta knockout (Ifnb-/-), and interferon 
regulatory factor 7 knockout (Irf7-/-) mice were bred and maintained in our mouse colony before 
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being transferred to the animal biosafety level 3 laboratory for CHIKV experiments. For some 
experiments, 4-week-old Vav-Cre+/-Ifnar1fl/fl or Vav-Cre− Ifnar1fl/fl littermate controls were used, 
which were also bred and maintained in our colony and genotyped prior to use in experiments. 
Ifnb-/-, Irf7-/-, and Vav-Cre+Ifnar1fl/fl mice bred onto the C57BL/6J background were generously 
provided by Michael S. Diamond (Washington University School of Medicine). 
Virus experiments 
 A recombinant strain of CHIKV (LR2006 OPY1) was generously provided by S. Higgs 
(Kansas State University) and generated from in vitro transcribed cDNA, as previously 
described177. At 4 weeks of age, mice were inoculated in the left rear footpad with 103 PFU of the 
LR2006 OPY1 strain of CHIKV in a volume of 10 μl. Infected mice were monitored daily for foot 
swelling with digital calipers for 14-15 days. At the termination of experiments, mice were sedated 
with a ketamine-xylazene cocktail and euthanized, and perfused via intracardiac injection with 
PBS. Tissues (ipsilateral left ankle, contralateral right ankle, and ipsilateral quadriceps muscle) 
were harvested into 0.65 mL PBS and then stored at −80°C until processing for viral burden. 
“Ankle” refers to distal foot with the skin and digits removed, and “foot” refers to the distal foot 
with cutaneous and subcutaneous tissues everted but still attached to the distal digits. For serum 
analysis, blood was collected at the time of sacrifice and centrifuged for 10 min at 10,000g and 
stored at −80°C. 
Tissue viral burden 
 Organs were harvested into 0.65 ml of PBS and homogenized with 1.0 mm diameter 
zirconia-silica beads with 2 pulses of 3,000 rpm for 30 seconds with a MagNA Lyser (Roche) prior 
to plaque assay on BHK cells. 200 μL of serial dilutions of organ homogenates or serum in DMEM 
with 1% FBS was added to BHK cells (5x105 cells for 6 well plates) and incubated for 1 hr at 37°C 
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with rocking every 20 min. An MEM-agar overlay was then added to the cells and incubated for 
approximately 60 hrs at 37°C or until plaques were visible by visual examination. Plates were then 
fixed with 1% formaldehyde (30 min at room temperature), and agar plugs were removed. Plaques 
were visualized using a 1% crystal violet solution and counted. 
Histopathological analysis 
 The ipsilateral feet of infected mice were treated with Nair® to remove the fur, and then 
the mice were sacrificed with a ketamine-xylazene cocktail and perfused by intracardiac injection 
of PBS at the indicated day post infection. The infected whole foot tissue (with the skin intact) was 
dissected above the ankle and fixed in 4% paraformaldehyde for 48 hours, followed by 
decalcification in 10 mL of 14% acid-free EDTA (pH 7.2) for 10-14 days, with the buffer changed 
every couple of days. Decalcified tissues were dehydrated with increasing ethanol gradients (30%, 
50%, and then 70%) and subsequently embedded in paraffin with 5-um sections prepared. Tissue 
sections were stained with hematoxylin and eosin (H&E). Embedding, sectioning, and staining 
were performed by the Musculoskeletal Histology and Morphometry Core. 
 For quantification of cells into the joint space, H&E slides were imaged with a Zeiss Axio 
Imager Z2 microscope equipped with a color CCD camera (Washington University Center for 
Cellular Imaging). The investigator was not blinded to the identity of the samples at the time of 
imaging, but all mid-foot synovial caps were imaged and then blinded for quantification by another 
investigator. The data are represented as the number of cells per high-power field (HPF). For 
overall inflammation scoring, the slides were blinded and scored by a pathologist. The pathologist 
noted the absence or presence of joint space inflammation, myositis, and tenosynovitis and then 
gave an overall inflammation score based on the following criteria: 0, no inflammation; 1, mild 
inflammation; 2, moderate inflammation; 3, severe inflammation. 
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Immune cell flow cytometry analysis 
 Mice were sacrificed 2 or 3 days after inoculation and perfused with PBS. The inoculated 
foot was disarticulated at the ankle without fracturing the bone. Cutaneous and subcutaneous tissue 
were everted but still attached to the distal foot and digits during digestion. Tissues were incubated 
for 2 hours at 37°C in 5 mL digestion buffer with manual shaking every 20-30 min. Digestion 
buffer consisted of RPMI (Sigma), type IV collagenase (2.5 mg/ml) (Sigma), DNase I (10 mg/ml) 
(Sigma), 15 mM Hepes (Corning), and 10% FBS (BioWest). Digested tissues were passed through 
a 70-um cell strainer and washed once with 40 mL PBS containing 4% FBS. The number of viable 
cells was quantified by trypan blue staining. 
 The single cell suspension was  transferred to a 96-well plate and incubated with anti-
mouse CD16/CD32 (Clone 93; BioLegend) for 10 min at 4°C and then surface-stained in PBS 
containing 4% FBS for 1 hour at 4°C with two separate panels of antibodies. All antibodies are 
from BioLegend unless otherwise specified. Panel 1 consisted of anti-MHC-II PerCP-Cy5.5 
(1:400, M5/114.15.2), anti-CD45 FITC (fluorescein isothiocyanate) (1:400, 30-F11), anti-CD11b 
Brilliant Violet 605 (1:200, M1/70), anti-CD3e (1:200, 145-2C11) and anti-CD19 (1:400, 1D3, 
BD Biosciences) Brilliant Violet 510 (dump gate), anti-CD11c Pacific Blue (1:200, N418), anti-
F4/80 APC-Cy7 (1:200, BM8), anti-Ly6C Alexa Fluor 700 (1:200, HK1.4), anti-MERTK PE 
(phycoerythrin) (1:200, 2B10C42), anti-Ly6G PE-Cy7 (1:200, 1A8), and Fixable Viability Dye 
eFluor 506 (1:500, eBioscience). Gating strategy for myeloid cells is illustrated in figure S2.1. 
 Panel 2 (data not shown) included anti-CD45 FITC (1:200, 30-F11), anti-CD11c Pacific 
Blue (1:200, N418), anti-CD19 APC-Cy7 (1:400, 6D5), anti-CD8α Alexa Fluor 700 (1:200, 53-
6.7), anti-CD3ε APC (1:200, 145-2C11), anti-CD4 PE-Cy7 (1:400, GK1.5), anti-NK1.1 PE 
(1:200, PK136), and Fixable Viability Dye eFluor 506 (1:500, eBioscience). Cells were washed 
54 
and fixed at 4°C for 10 min in 4% paraformaldehyde (Electron Microscopy Sciences). The fixed 
cells were washed and resuspended in PBS containing 4% FBS. Cells were run on a LSR Fortessa 
(Becton Dickinson) flow cytometer and analyzed using BD FACSDiva and FlowJo V10 software. 
In vivo IFN blockade 
 BL6 mice were administered 1 mg of anti-mouse pan-IFN-α (TIF-3C5), 1 mg of anti-
mouse IFN-β (HDb-4A7), or 1mg isotype control (PIP) (Leinco, St. Louis, MO) at 24h prior to 
and again 24h post infection by an intraperitoneal route. 
In vivo neutrophil depletion 
 BL6, IFN-β-KO, or IRF7-KO mice were treated with 0.25 mg of anti-mouse Ly6G (1A8) 
or isotype control (Leinco, St. Louis, MO) at 1 day before and every other day through 7 days post 
infection by intraperitoneal route. Neutrophil depletion was verified by whole blood staining at 6 
or 8 dpi (data not shown). 
Cytokine and chemokine analysis 
 Foot tissues (with the cutaneous and subcutaneous tissues everted but still attached to the 
distal foot and digits) were harvested from euthanized infected mice at days 2 and 3 and collected 
in 500 μL PBS with 0.1% BSA added and then homogenized using a MagNA Lyser (Roche). 
Cytokine and chemokine levels in the homogenates were measured using Luminex technology 
with a mouse 25-plex assay, as per the manufacturer’s instructions (Millipore). 
Quantification and Statistical Analysis 
 All statistical analyses were performed with GraphPad Prism 7 software (San Diego, CA). 
For foot swelling over time and viral burden analysis (3 experimental groups), two-way ANOVA 
with Dunnet’s post-hoc multiple comparisons analysis was used. For cytokine/chemokine and 
infiltrate analyses (2 experimental groups), two-way ANOVA with Sidak’s post-hoc multiple 
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comparisons was used. For histological scoring and cells/HPF quantification one-way ANOVA 
with Tukey’s post-hoc multiple comparisons test was used. All sample sizes were determined 
based on our extensive experience with this model. P < 0.05 indicated statistically significant 
differences.  
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2.6 Figures 
 
Figure 2.1 IFN-α and IFN-β both play protective roles in limiting clinical CHIKV disease 
Mice were inoculated with 103 pfu of CHIKV (La Réunion) subcutaneously in the left rear foot pad. (A-B) 
Foot swelling was measured daily for WT, IFN-β-KO, or IRF7-KO mice (A) or WT mice treated with 1 
mg of anti-mouse IFN-α (TIF-3C5), 1 mg anti-mouse IFN-β (HDβ-4A7), or 1 mg isotype control antibody 
at 24 hours prior to and post infection by intraperitoneal (IP) route (B). Data are reported as percent increase 
in foot area (vertical x horizontal mm2) over baseline. Data are pooled from at least 2 independent 
experiments with n = 18-22 mice per group (A) or n = 10 mice per group (B). All data are represented as 
mean ± SEM, and if no error bar is present that indicates the error is smaller than the height of the symbol. 
*, p<0.05; **, p<0.01; ***, p<0.001; ****, p<0.0001 (2-way repeated measure ANOVA with Dunnett’s 
post-hoc multiple comparisons analysis). 
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Figure 2.2 IFN-β-KO, but not IRF7-KO, mice have increased cellular infiltration into the midfoot joint 
spaces during acute CHIKV infection 
Infected (103 pfu CHIKV) or mock-inoculated animals were sacrificed at 7 dpi, and histology of the 
ipsilateral foot was performed. (A-B) Representative hematoxylin and eosin (H&E) staining of the 
ipsilateral mid-foot joints in CHIKV-infected (A) or mock-inoculated mice (B) at 7 dpi (scale bar = 100 
μm). (C) H & E slides were scored on a scale of 0 to 3 by a blinded pathologist for overall inflammation, 
taking into consideration joint space inflammation, myositis, and synovitis for scoring. Criteria were: 0, no 
inflammation; 1, mild inflammation; 2, moderate inflammation; 3, severe inflammation. (D) A blinded 
investigator counted the number of inflammatory cells per high-power field (HPF) in the midfoot synovial 
spaces. Data are depicted as the mean ± SEM. Histological results are at least two independent experiments 
pooled with n = 4-6 per group. *, p<0.05; **, p<0.01; ***, p<0.001 (1-way ANOVA with Tukey’s post-
hoc multiple comparisons analysis). 
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Figure 2.3 IFN-α, but not IFN-β, limits CHIKV replication and dissemination 
Mice were inoculated with 103 pfu of CHIKV and then sacrificed and perfused with PBS at the indicated 
time points. Infectious virus in the joints, muscle, and serum were determined by plaque assay in BHK cells 
in (A) WT, IFN-β-KO mice, or IRF7-KO mice or (B) WT mice administered 1 mg anti-IFN-α, 1 mg anti-
IFN-β, or 1 mg isotype control by IP route at 24 h prior to and 24 h post infection. Dashed line represents 
the limit of detection. Data are represented as median ± SEM. *, p<0.05; **, p<0.01; ***, p<0.001; ****, 
p<0.0001 (2-way ANOVA followed by Dunnett’s post-hoc multiple comparisons test). 
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Figure 2.4 IFN-α and IFN-β exert their protective effects during CHIKV arthritis by signaling on 
nonhematopoietic cells 
Vav-Cre+ IFNAR1flox/flox mice or Cre- IFANR1flox/flox littermate controls were infected with 103 pfu of 
CHIKV (La Réunion). (A) Foot swelling was measured daily with digital calipers. Results are pooled from 
2 independent experiments with n = 6-9 mice per group. Data are represented as the mean ± SEM. The 
results were not statistically significant (p > 0.05) by 2-way repeated measure ANOVA with Dunnett’s 
post-hoc multiple comparisons analysis. (B) Infectious virus in the joints, muscle, and serum were 
determined by plaque assay at the indicated time points. Data are represented as median ± SEM. 
*, p<0.05 (2-way ANOVA followed by Dunnett’s post-hoc multiple comparisons test).  
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Figure 2.5 IFN-β deficient mice have increased neutrophil recruitment into the ipsilateral foot during 
CHIKV infection 
Mice were inoculated with 103 pfu of CHIKV via a subcutaneous route. The ipsilateral foot tissue was 
collected at 2 and 3 dpi and digested with Collagenase IV (Sigma). The single cell suspension was surface 
stained for immune cell markers and analyzed by flow cytometry. (A) Representative FACS plots showing 
the percentages of CD11b+Ly6G+ neutrophils isolated from the feet of WT or IFN-β-KO mice at 2 dpi. B. 
(B) Total number of isolated CD45+ leukocytes and total number or percentage of CD11b+Ly6G+ 
neutrophils, CD11b+Ly6C+Ly6G- monocytes, and F4/80+MERTK+ macrophages. Results are pooled from 
2 independent experiments with n = 6-7 mice per group. Data represent the mean ± SEM. *, p<0.05; ****, 
p<0.0001 (2-way ANOVA with Sidak’s post-hoc multiple comparisons test). 
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Figure 2.6 Mice lacking IFN-β have increased early IL-9 levels in the ipsilateral foot 
Mice were inoculated with 103 pfu of CHIKV via a subcutaneous route. Cytokine and chemokine levels on 
day 2 and 3 in the ipsilateral foot was determined using Luminex technology (Millipore). Results are pooled 
from two independent experiments with n = 6-7 mice per group. Data represent the mean ± SEM. Dashed 
line represents limit of detection. *, p<0.05; ****, p<0.0001 (2-way ANOVA with Sidak’s post-hoc 
multiple comparisons test). 
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Figure 2.7 Depletion of neutrophils alleviates the increased foot swelling seen in CHIKV-infected IFN-
β-KO mice, but not in IRF7-KO mice 
WT, IFN-β-KO, or IRF7-KO mice were infected with 103 pfu of CHIKV. Mice were administered 0.25 mg 
anti-Ly6G (1A8) or isotype control antibody by IP route beginning at 1 day before and continued every 
other day through 7 dpi. Foot swelling was monitored daily and is reported as percent increase in foot area 
(vertical x horizontal mm2) over baseline. Results are pooled from 2 independent experiments with n = 5-8 
mice per group. Data are reported as the mean ± SEM. **, p<0.01; ***, p<0.001; **** p<0.0001 (2-way 
repeated measure ANOVA with Dunnett’s post-hoc multiple comparisons analysis). 
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Figure S2.1 Gating strategy to identify myeloid cells recruited into the ipsilateral foot during CHIKV 
infection 
Mice were inoculated with 103 pfu of CHIKV via a subcutaneous route. The ipsilateral foot tissue was 
collected at 2 and 3 dpi and digested with Collagenase IV (Sigma). The single cell suspension was surface 
stained for immune cell markers and analyzed by flow cytometry. Gating strategy for WT and IFN-β-KO 
mice at 2 dpi is shown. Gates were drawn based on an unstained sample. 
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Chapter 3 
Therapy with CTLA4-Ig and an antiviral monoclonal 
antibody controls chikungunya virus arthritis 
 
 
This chapter contains data published in the following publication with significant contribution 
from Jonathan Miner. 
J. J. Miner*, L. E. Cook*, J. P. Hong, A. M. Smith, J. M. Richner, R. M. Shimak, A. R. Young, 
K. Monte, S. Poddar, J. E. Crowe Jr., D. J. Lenschow, M. S. Diamond, Therapy with CTLA4-Ig 
and an antiviral monoclonal antibody controls chikungunya virus arthritis. Sci. Transl. Med. 9, 
eaah3438 (2017). 
*co-first authors 
  
65 
3.1 Abstract 
 In 2013, chikungunya virus (CHIKV) transmission was documented in the Western 
Hemisphere, and the virus has since spread throughout the Americas with more than 1.8 million 
people infected in more than 40 countries. CHIKV targets the joints, resulting in symmetric 
polyarthritis that clinically mimics rheumatoid arthritis and can endure for months to years. At 
present, no approved treatment is effective in preventing or controlling CHIKV infection or 
disease. We treated mice with eight different disease-modifying antirheumatic drugs and identified 
CLTA4-Ig (abatacept) and tofacitinib as candidate therapies based on their ability to decrease acute 
joint swelling. CTLA4-Ig reduced T cell accumulation in the joints of infected animals without 
affecting viral infection. Whereas monotherapy with CTLA4-Ig or a neutralizing anti-CHIKV 
human monoclonal antibody provided partial clinical improvement, therapy with both abolished 
swelling and markedly reduced levels of chemokines, proinflammatory cytokines, and infiltrating 
leukocytes. Thus, combination CTLA4-Ig and antiviral antibody therapy controls acute CHIKV 
infection and arthritis and may be a candidate for testing in humans. 
3.2 Introduction 
 Chikungunya virus (CHIKV) is a mosquito-transmitted alphavirus that causes severe acute 
and chronic polyarthritis. CHIKV was first isolated in Tanzania in 1947, but the virus has emerged 
rapidly over the last decade, causing outbreaks in the islands of the Indian Ocean, in Southern 
Europe, and in Southeast Asia178,179. In 2013, CHIKV spread to the Western Hemisphere and, by 
the end of 2015, had infected more than 1.8 million people in North America, Central America, 
and South America. The acute symptoms of CHIKV infection include fever and rash, which 
typically resolve within a few days, and joint and muscle pain23. CHIKV and other arthritogenic 
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alphaviruses directly invade the synovium to cause inflammatory arthritis, which is characterized 
by articular swelling and prolonged morning stiffness23,52. CHIKV-induced arthritis in humans can 
persist, with as many as 60% of individuals progressing to chronic disease that lasts from months 
to years20,23,180,181. Epidemiological projections suggest that there are currently about 400,000 
individuals in the Western Hemisphere with chronic CHIKV arthritis22. 
 Chronic CHIKV arthritis clinically is similar to seronegative rheumatoid arthritis (RA), an 
autoimmune disease characterized by symmetrical joint pain, swelling, and morning stiffness23,182–
184. Treatment with newer disease-modifying antirheumatic drugs (DMARDs) has been effective 
in preventing the bone erosions and deformities seen in patients with untreated RA. Whether 
chronic CHIKV arthritis causes erosive disease remains controversial, although there are reports 
of bone erosions in patients infected with CHIKV182. Effective treatment of RA relies on early 
diagnosis, because erosions can occur within months of onset of the disease185. Because CHIKV 
and RA exhibit significant clinical overlap, there is potential for confusing the diagnoses and 
inadvertently treating CHIKV arthritis with DMARD therapy23. 
 Over the last 20 years, studies in patients with RA have demonstrated that oral and 
biological DMARDs prevent joint pain, swelling, and damage. Oral DMARDs include 
hydroxychloroquine, methotrexate, and sulfasalazine, whereas biological DMARDs include the 
anticytokine antibodies and Ig chimeras [for example, anti–tumor necrosis factor–α (TNF-α) and 
anti–interleukin-6 (IL-6) receptor]. Other biological DMARDs block T cell costimulation 
(CTLA4-Ig) or deplete B cells (anti-CD20). Among the newest drugs used to treat RA is 
tofacitinib, an oral DMARD that inhibits JAK (Janus kinase)/STAT (signal transducers and 
activators of transcription) signaling and broadly blunts cytokine responses186,187. However, many 
DMARDs, by virtue of their immunosuppressive properties, may predispose to serious microbial 
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infections. Thus, there is a need to determine whether DMARDs are effective, benign, or 
deleterious in the treatment of CHIKV arthritis. The current standard of care for CHIKV arthritis 
is treatment with nonsteroidal anti-inflammatory drugs (NSAIDs), although these often do not 
ameliorate symptoms23,26. One trial compared chloroquine (a DMARD) to meloxicam (an NSAID) 
and found no difference in efficacy, although a placebo group was not included in the trial design26. 
Another open-label study examined a combination of hydroxychloroquine and methotrexate in the 
treatment of CHIKV arthritis and found that some patients partially responded to therapy, although 
~50% of patients did not achieve significant improvement in disease score188. 
 Subcutaneous inoculation of young wild-type (WT) immunocompetent C57BL/6 mice 
with pathogenic strains of CHIKV results in acute foot swelling, myositis, and arthritis51,52. In this 
model, swelling resolves within the first 2 weeks of infection, although mild chronic disease can 
be observed histologically for weeks to months51,52,189. This finding contrasts with the disease in 
humans, which are natural hosts and frequently have a protracted clinical disease course. Human 
patients with CHIKV arthritis have increased numbers of circulating, activated cytolytic CD8+ T 
cells, as do patients with untreated RA23. Gene expression signatures observed in mouse models 
of CHIKV arthritis and RA suggested overlapping contributions of T cell–associated pathways in 
these diseases190. Mice lacking or depleted of CD4+ T cells have reduced foot swelling and arthritis 
during acute CHIKV infection, suggesting that CD4+ T cells contribute to the pathology of 
arthritis79. Inflammatory monocytes also are thought to play an initiating role in CHIKV arthritis 
in mice, because inhibiting production of monocyte chemoattractant protein-1 (MCP-1) with 
bindarit improved the disease191. Finally, treatment of mice with anti-CHIKV monoclonal 
antibodies (mAbs) 1 day before infection prevents arthritis, but whether therapy after infection is 
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effective has not been studied29,192,193. Moreover, no previous study has tested the efficacy of 
clinically available DMARDs against CHIKV arthritis in mice. 
 Here, we examined the efficacy of several U.S. Food and Drug Administration (FDA)–
approved RA therapies in a mouse model of CHIKV infection. We identified two DMARDs 
(CTLA4-Ig and tofacitinib) with efficacy during acute CHIKV arthritis. In particular, CTLA4-Ig, 
when paired with the neutralizing anti-CHIKV human mAb 4N12, was highly effective at reducing 
joint inflammation, periarticular swelling, migration of inflammatory leukocytes, and infection 
even when administered several days after virus inoculation. Thus, combination of anti-
inflammatory and antibody-based antiviral therapy may serve as a model for treating humans with 
arthritis caused by CHIKV or other related viruses. 
3.3 Results 
 Screen of candidate oral and biological DMARDs for treatment of acute CHIKV 
arthritis in mice. On the basis of previous data showing that immune cells and proinflammatory 
cytokines contribute to CHIKV arthritis in mice and our study showing that CHIKV arthritis 
clinically can mimic seronegative RA, we hypothesized that some of the existing FDA-approved 
therapies for RA might ameliorate acute CHIKV arthritis23,79. To test this idea, we performed a 
multiarm prospective study (Fig. 3.1A) by inoculating 224 4-week-old WT mice subcutaneously 
in the left rear foot with 103 focus-forming units (FFU) of a pathogenic clinical isolate of CHIKV 
(La Reunion, 2006). Mice were divided into groups of 28 animals that received one of the 
following treatments beginning on day 3 after infection: methylprednisolone, naproxen, 
methotrexate, etanercept (soluble human TNF-α receptor), CTLA4-Ig (abatacept), oral gavage 
vehicle control, or tofacitinib (JAK inhibitor). All of the biological agents that we used have been 
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shown previously to have activity in mice186,194,195. We chose day 3 after infection to initiate 
treatment, because this represents the time point of the first peak of clinically apparent foot 
swelling in the WT C57BL/6 mouse model of CHIKV infection (Fig. 3.1B). Animals were 
followed for clinical joint swelling in the ipsilateral foot and viral yield at different times after 
infection and treatment. 
 Treatment with CTLA4-Ig or tofacitinib at day 3 ameliorated foot swelling on day 7 after 
infection at the point of peak clinical disease [Fig. 3.1, C to F; 9.0 mm2 (injection control) versus 
7.8 mm2 (CTLA4-Ig), P < 0.005 and 9.3 mm2 (oral control) versus 8.5 mm2 (tofacitinib), P < 
0.005]. Other treatments had no significant effect at the dose tested in our experiments. To assess 
the systemic and local impact on viral burden of DMARD treatment, we evaluated CHIKV RNA 
levels on day 7 in serum and joint tissues. Remarkably, none of the therapies affected viral RNA 
levels in the right ankle or left ankle at day 7 or day 28 after infection compared to controls (Fig. 
3.1, G to J; P > 0.1). Thus, CTLA4-Ig and tofacitinib ameliorate joint and periarticular 
inflammation in mice during the acute phase without substantively altering the viral burden in 
inflamed tissues. The beneficial effect of CTLA4-Ig, which blocks T cell activation, is consistent 
with data suggesting that CD4+ T cells contribute to immunopathology associated with CHIKV 
arthritis79,194. 
 Combination therapy with CTLA4-Ig and an anti-CHIKV human mAb ameliorates 
acute CHIKV arthritis in mice. We next tested whether combination immunomodulatory and 
antiviral therapy might have greater beneficial effects. Potently neutralizing human anti-CHIKV 
mAbs previously were shown to protect against CHIKV-induced lethality in immunocompromised 
Ifnar1−/− mice, even when administered at late time points after infection28. We administered either 
a single 600-μg dose of a control immunoglobulin G (IgG), 300 μg of CTLA4-Ig, 300 μg of anti-
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CHIKV mAb (4N12, a neutralizing anti-CHIKV human mAb), or 300 μg each of CTLA4-Ig + 
anti-CHIKV mAb (Fig. 3.2A) 3 days after CHIKV infection. Whereas either anti-CHIKV mAb or 
CTLA4-Ig partially reduced foot swelling at day 7, the combination completely abolished it (10.8 
mm2 versus 6.6 mm2, P < 0.0001) relative to untreated or control IgG–treated animals (Fig. 3.2, A 
and B). Thus, anti-CHIKV mAb therapy initiated after disease onset can partially treat the acute 
clinical arthritis associated with CHIKV infection, and combination therapy with anti-CHIKV 
mAb and the immunomodulator CTLA4-Ig completely resolves clinical disease in mice within a 
few days of treatment. 
 Viral burden in CHIKV-infected mice treated with CTLA4-Ig and anti-CHIKV mAb. 
To confirm the activity of the anti-CHIKV mAb in this model, we assessed its effects on viral 
burden. Treatment with anti-CHIKV mAb (alone or in combination with CTLA4-Ig) at day 3 
eliminated infectious virus in the joints of infected mice within 2 days, as we observed a ~10,000-
fold reduction in the ipsilateral ankle (Fig. 3.3A; P < 0.0005) and a ~100-fold reduction in the 
contralateral ankle (Fig. 3.3A; P < 0.05). Viral burden in mice treated with only CTLA4-Ig was 
not reduced in either the ipsilateral or contralateral ankle (Fig. 3.3A). Although infectious CHIKV 
cannot be detected after day 7 in this mouse model (or during the chronic phase in humans), 
CHIKV RNA persists in joint tissues for months23,52,54. Because persistent viral RNA is a 
pathogen-associated molecular pattern and may contribute to CHIKV arthritis, we tested whether 
anti-CHIKV mAb treatment would reduce viral RNA levels23,54. Although we did not observe a 
reduction in viral RNA levels in the ipsilateral foot joints (P > 0.1), other extremity joints exhibited 
a ~10-fold reduction in viral RNA on day 7 after infection, including the contralateral ankle and 
ipsilateral wrist (Fig. 3.3B; right ankle, P < 0.005; left wrist, P < 0.05). On day 28, there was a 
trend toward reduced RNA in distal joint tissues of animals treated with anti-CHIKV mAb, 
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although this did not attain statistical significance (Fig. 3.3C; P = 0.2). Collectively, these results 
show that treatment with an anti-CHIKV mAb (alone or in combination with CTLA4-Ig) rapidly 
eliminates infectious virus within 2 days and reduces but fails to clear viral RNA in affected 
tissues. 
 Cytokine and chemokine analysis in CHIKV-infected mice treated with CTLA4-Ig 
and anti-CHIKV mAb. To begin to define the basis for reduced joint swelling associated with 
treatment, we analyzed the effects on local cytokine and chemokine production. Using a 
multiplexed assay, we measured cytokine and chemokine levels in the ipsilateral foot on day 7 
after infection in animals that received either control mAb, CTLA4-Ig, anti-CHIKV mAb, or 
combination therapy with CTLA4-Ig and anti-CHIKV mAb. Monotherapy with CTLA4-Ig 
reduced levels of CXCL10 and macrophage inflammatory protein-1β (MIP-1β) (Fig. 3.4, A and 
B; P < 0.05), whereas treatment with anti-CHIKV mAb reduced levels of MCP-1 (Fig. 3.4C; P < 
0.05). In comparison, combination therapy had more profound anti-inflammatory effects and 
resulted in decreased levels of many of the measured chemokines (for example, KC, CXCL10, 
MCP-1, MIP-1β, and RANTES; Fig. 3.4, A to I; P < 0.05) in the joint tissue. 
 Histological and immune infiltrate analysis of the ipsilateral midfoot joints in 
CHIKV-infected mice treated with CTLA4-Ig and anti-CHIKV mAb. Histological analysis of 
joint tissues in the ipsilateral foot revealed reduced leukocyte infiltration into the midfoot joints of 
mice receiving CTLA4-Ig and combination therapy with CTLA4-Ig and anti-CHIKV mAb (Fig. 
3.5, A to F; yellow arrows, moderate to severe synovitis; white arrows, absent or mild synovitis). 
We next quantitated the number of inflammatory cells per high-power field (HPF) in the synovial 
space of the midfoot. CTLA4-Ig and combination therapy with CTLA4-Ig and anti-CHIKV mAb 
resulted in decreased inflammatory cell infiltration into the synovial space (52 cells per HPF in the 
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control group, 22 cells per HPF in CTLA4-Ig group, and 9 cells per HPF in the CTLA4-Ig + anti-
CHIKV mAb group, P < 0.05 and P < 0.0001, respectively). Histological analysis did not reveal 
evidence of bone erosion, proteoglycan loss, or effects on expression of receptor activator of 
nuclear factor kappa-B ligand (RANKL) and osteoprotegerin (OPG) (fig. S3.1). Consistent with a 
role for CTLA4-Ig in modulating immune cell recruitment, administration of CTLA4-Ig 1 day 
before infection resulted in reduced swelling on day 7 but not on day 3 (fig. S3.2), a time point at 
which subcutaneous edema but not immune cell infiltration is observed. To quantitate differences 
in immune cell infiltration into the entire foot at day 7 after infection, we analyzed by flow 
cytometry how CTLA4-Ig and anti-CHIKV mAb treatments affected the total numbers of immune 
cells in the soft tissues of the ipsilateral foot, which included the skin, muscle, and joints. After 
treatment with CTLA4-Ig or a combination of CTLA4-Ig and anti-CHIKV mAb, we observed 
about a three- to fourfold reduction in the number of total CD45+ leukocytes (Fig. 3.6, A and B; P 
< 0.0005) with markedly reduced numbers of Ly6C+CD11b+ inflammatory monocytes, natural 
killer cells, and CD8+ T cells, and a nearly complete absence of CD4+ T cells (Fig. 3.6, B to G). 
By contrast, treatment with the anti-CHIKV mAb alone did not reduce the number of infiltrating 
CD45+ cells or individual leukocyte subsets into the infected foot (Fig. 3.6, A to G). 
 Clinical assessment of the response to CTLA4-Ig treatment in CHIKV-infected WT 
and TCRβδ−/− mice. CTLA4-Ig blocks T cell costimulation, but it can also have 
immunomodulatory effects on antigen-presenting cells (APCs)194,196. Human CTLA4-Ig, which 
was used in our studies, binds murine B7.1 and B7.2 antigens and can modulate APC 
function197,198. We assessed APC activation on day 7 after infection but saw no difference in CD80, 
CD86, and class II major histocompatibility complex marker expression in APCs isolated from the 
spleen and feet of control and CTLA4-Ig–treated mice (fig. S3.3). To test whether CTLA4-Ig 
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exerted its therapeutic benefits via T cells, we compared the response to CTLA4-Ig and a control 
mAb in CHIKV-infected WT and TCRβδ−/− mice, the latter of which lack both αβ and γδ T cells. 
As we observed a beneficial effect of CTLA4-Ig in WT animals (Fig. 3.7, A and C; P < 0.005) but 
not in TCRβδ−/− mice (Fig. 3.7, B and C; P > 0.9), CTLA4-Ig reduces swelling during acute 
CHIKV infection in part via its action on T cells. 
3.4 Discussion 
 The worldwide emergence of CHIKV has created a need to identify treatments, as 
epidemiological estimates suggest there are millions suffering from acute arthritis and at least 
~400,000 people in the Western Hemisphere suffering from chronic CHIKV arthritis22,180. We 
reasoned that established therapies used to treat other forms of inflammatory arthritis (for example, 
rheumatoid or psoriatic arthritis) also might mitigate CHIKV arthritis. Our experiments identified 
CTLA4-Ig and tofacitinib as candidate DMARD therapies based on efficacy against acute CHIKV 
arthritis in mice. 
 Immunopathology likely contributes to the pathogenesis of CHIKV arthritis. Previous 
studies using Rag2−/− animals suggested that the response depends on B and T cells, because 
Rag2−/− animals had no ipsilateral foot swelling79. Leukocyte subsets infiltrating the peripheral 
joints of CHIKV-infected mice primarily consist of T cells, inflammatory monocytes, and 
macrophages52. When we blocked T cell costimulation with CTLA4-Ig, we observed reduced 
infiltration of T cells and inflammatory monocytes into the joints of infected animals, although 
this was not sufficient to eliminate the clinical disease completely. Treatment of TCRβδ−/− mice 
with CTLA4-Ig had no effect on joint swelling, suggesting that CTLA4-Ig ameliorates clinical 
disease primarily via its action on T cells. These findings are consistent with previous studies 
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suggesting that joint swelling in the foot of CD4−/− animals is reduced in severity but not 
completely controlled79. Our findings suggest that other inhibitors of CD4+ T cell function also 
might limit musculoskeletal disease associated with CHIKV infection. Teo et al. recently 
demonstrated that treatment with fingolimod, an agonist of the sphingosine 1-phosphate receptor, 
limited infiltration of CD4+ T cells into CHIKV-infected joints and adjacent muscle in mice, 
resulting in reduced joint swelling and muscle necrosis199. 
 Previous studies showed that mouse and human antiviral antibodies could prevent CHIKV 
arthritis in mice when administered before infection or protect against lethality in highly 
immunocompromised Ifnar1−/− mice28,54,192. We found that treatment of WT mice 3 days after 
CHIKV infection with an antiviral human mAb reduced but did not eliminate joint swelling, 
although infectious virus could not be detected in the joints within 2 days of therapy. Foot swelling 
likely depends on multiple factors including synovitis, myositis, and edema resulting from 
production of proinflammatory cytokines52. The anti-CHIKV mAb eliminated infectious virus 
within 2 days of its administration and reduced foot swelling without altering leukocyte infiltration 
into joints of infected animals, suggesting that leukocyte recruitment is not the only factor that 
affects disease severity in this model. Local cytokine production in specific compartments (for 
example, serum, muscles, or joints) independently may affect the virus-induced swelling or edema. 
Future histological studies may define better the precise mechanism by which neutralization of 
infectious CHIKV by antiviral antibodies ameliorates foot swelling. 
 The type I interferon (IFN-I) response is important in controlling CHIKV infection. 
Ifnar1−/− mice lacking type I IFN signaling are highly vulnerable to disseminated infection with 
CHIKV and succumb within days due to high levels of virus in the brain and spinal cord56. 
Remarkably, treatment with tofacitinib, which blocks JAK/STAT signaling that is downstream of 
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IFNAR1 and other cytokine receptors, reduced clinical disease without ostensible effects on 
morbidity or mortality. This result may be related to the pharmacodynamics of tofacitinib 
including its short half-life186. Tofacitinib therapy may blunt cytokine production and/or leukocyte 
infiltration without enhancement of CHIKV replication. Nevertheless, because tofacitinib is 
known to enhance the risk of some viral infections, including varicella zoster virus, future 
combination therapy studies with tofacitinib and an antiviral mAb may be warranted200. 
 Anecdotal reports in humans have suggested that methotrexate may be effective for 
treatment of CHIKV arthritis188,201. In our studies, a low dose of methotrexate did not provide 
benefit against acute arthritis. It remains possible that methotrexate would show greater benefit if 
higher doses were used. Mouse models of Ross River virus arthritis previously revealed 
exacerbation of disease after treatment with etanercept, whereas an uncontrolled study in humans 
suggested that blockade of TNF-α provided some benefit in 13 patients who were diagnosed with 
a “chronic rheumatologic disease” after acute CHIKV infection201,202. However, it is important to 
note that some patients infected with CHIKV may develop rheumatologic disease sporadically or 
coincidentally after CHIKV infection. In a controlled study of mice infected with CHIKV, we did 
not find a benefit of etanercept therapy with acute CHIKV arthritis, but we were unable to assess 
chronic disease because of the histopathological absence of frank arthritis during the chronic 
phase. In light of our animal model results and the anecdotal nature of previous human studies, it 
seems that rigorous, blinded, placebo-controlled studies in human patients are necessary to define 
which DMARD therapies may be safe and optimal in patients with chronic CHIKV arthritis. 
 CHIKV and related arthritogenic alphaviruses directly invade the joints and leave 
persistent viral RNA in the joints and surrounding tissues even in the absence of detectable 
infectious virus54. In previous studies, we found that most CHIKV-infected control C57BL/6 mice 
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did not exhibit histopathological evidence of chronic arthritis 1 month after infection, although 
there was mild chronic tenosynovitis and myositis in some animals52. Because we could readily 
detect viral RNA in the joints at day 28, our studies suggest that persistent viral RNA may not be 
sufficient to cause clinically apparent chronic arthritis in mice and that other factors must 
contribute to pathogenesis. Thus, it remains to be determined whether our combination treatment 
with an antiviral antibody and CTLA4-Ig has beneficial effects in chronic CHIKV arthritis. Other 
animal models with more severe chronic disease (for example, nonhuman primates) may be 
required to address these questions. 
 The beneficial effects of CTLA4-Ig and antiviral antibody therapy on CHIKV arthritis 
must be interpreted with caution because there are limitations with the mouse model. Unlike 
humans, mice are not natural hosts for CHIKV and therefore do not develop the severe, debilitating 
arthritis that is commonly observed in humans. Because CHIKV causes less severe disease in mice, 
it remains possible that immunomodulatory therapies, including CTLA4-Ig, may have no or even 
deleterious effects in humans. 
 The concept of combination antiviral and immunomodulatory therapy is a unique approach 
for the treatment of infectious diseases. The near-complete effectiveness of combination therapy 
in our mouse model of acute CHIKV arthritis has implications for treatment of other viral 
infections in which both virus- and immune-mediated pathology result in morbidity and mortality 
(for example, influenza and severe acute respiratory syndrome coronavirus). Given the large 
number of clinically available biological and small molecular DMARDs, this work may provide 
greater impetus for studies that test combination antiviral and immunomodulatory therapies for the 
treatment of infectious diseases. 
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3.5 Materials and Methods 
Study design 
 We initiated this study to determine whether anti-inflammatory and antiviral therapy 
control acute CHIKV arthritis in mice. Our initial observation was that treatment with antiviral 
antibody reduced infectious viral burden in the ipsilateral joint and that therapy with CTLA4-Ig 
diminished recruitment of T cells and inflammatory monocytes as well as the accumulation of 
proinflammatory cytokines. Subsequent histological analysis confirmed these findings. We 
measured viral titers and RNA in tissues, immunologic parameters (including influx of specific 
cell subtypes into the joints and surrounding tissues), and cytokine levels. Sample sizes and end 
points were selected on the basis of our extensive experience with these systems. Mice were age- 
and sex-matched between groups. Histological analysis was performed in a blinded fashion. Initial 
footpad measurements were performed by three individuals in an unblinded fashion. However, the 
measurements after CTLA4-Ig treatment were reproduced by a fourth individual who performed 
a blinded assessment. Investigators were not blinded when conducting virus tissue burden analysis, 
cytokine measurements, or flow cytometry analysis. 
Mouse experiments 
 All animal experiments were performed in accordance and with approval of Washington 
University Institutional Animal Care and Use Committee guidelines, and all mouse infection 
studies were performed in an animal biosafety level 3 laboratory. All experiments were performed 
with 4-week-old C57BL/6 mice or with TCRβδ−/− mice that were obtained commercially (The 
Jackson Laboratories). 
Virus infection studies 
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 A recombinant LR2006 OPY1 strain of CHIKV was provided by S. Higgs (Kansas State 
University) and generated from in vitro transcribed cDNA, as previously described177. At 4 weeks 
of age, mice were inoculated in the left rear footpad with 103 FFU of the LR2006 OPY1 strain of 
CHIKV in a volume of 10 μl. Infected mice were monitored daily for foot swelling with digital 
calipers for 28 days. At the termination of experiments, mice were sedated with a ketamine-
xylazene cocktail and euthanized, and perfused via intracardiac injection with PBS. Tissues 
(injected left ankle, contralateral ankle, and ipsilateral wrist) were harvested and snap-frozen on 
dry ice and stored at −80°C until processing for RNA isolation. For serum analysis, blood was 
collected at the time of sacrifice and centrifuged for 10 min at 10,000g and stored at −80°C. In 
some experiments, serum and joint tissues were isolated from mice on day 5 after infection for 
subsequent analysis by focus-forming assay. 
Tissue viral burden analysis 
 Focus-forming assays were performed as previously described192. Briefly, tissue 
homogenates or serum were incubated for 90 min on a monolayer of Vero cells in 96-well plates, 
and then cells were overlaid with 1% (w/v) methylcellulose in modified Eagle media supplemented 
with 4% fetal bovine serum (FBS). Plates were harvested 18 to 24 hours later and fixed with 1% 
paraformaldehyde (PFA) in PBS. The plates were incubated sequentially with chimeric CHK-9 
(500 ng/ml)192 and horseradish peroxidase–conjugated goat anti-human IgG in PBS supplemented 
with 0.1% saponin and 0.1% bovine serum albumin. CHIKV-infected foci were visualized using 
TrueBlue peroxidase substrate (KPL) and quantitated on an ImmunoSpot 5.0.37 macroanalyzer 
(Cellular Technologies Ltd). 
Real-time qRT-PCR analysis 
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 RNA was extracted from tissue using the RNeasy Mini Kit (Qiagen). The quantity of 
CHIKV RNA was determined by qRT-PCR using the TaqMan RNA-to-CT 1-Step Kit (Applied 
Biosystems) with an E1-specific primer/probe set203. Two microliters of the isolated RNA was 
analyzed by qRT-PCR and compared to a standard curve generated from RNA isolated from a 
CHIKV stock to determine FFU equivalents. 
Therapeutic agents 
 4N12 is a human IgG1 mAb that neutralizes CHIKV infection and has been described 
previously28. Antibody was purified from hybridoma supernatants by protein G affinity 
chromatography. Methotrexate, CTLA4-Ig (abatacept), and etanercept were obtained from the 
Center for Advanced Medicine Rheumatology Clinic (St. Louis, MO). Naproxen sodium and 
methylprednisolone acetate were purchased from Sigma. The isotype control antibody [humanized 
anti–West Nile virus antibody (E16)] was produced in Chinese hamster ovary cells and purified 
by protein G affinity chromatography204. 
Histopathological analysis 
 Infected mice were sacrificed and perfused by intracardiac injection of 4% PFA at the 
indicated days after infection. The infected ankle/foot tissue was dissected and fixed in 4% 
PFA/PBS for 48 hours, followed by decalcification in 14% acid-free EDTA for 10 to 14 days. 
Decalcified tissues were embedded in paraffin, and 5-μm sections were stained with hematoxylin 
and eosin (H&E) and evaluated by light microscopy. Embedding, sectioning, and staining were 
performed by the Musculoskeletal Histology and Morphometry Core at Washington University 
School of Medicine. All samples were visualized using a Nikon Eclipse microscope equipped with 
a QICAM 12-bit camera (QImaging) and processed with QCapture software using the same 
exposure times. 
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Cytokine/chemokine analysis 
 Ankles were harvested from euthanized infected mice at day 7 and collected in 500-μl PBS 
and homogenized using a MagNA Lyser (Roche). Cytokine levels were measured using Luminex 
technology with a Bio-Plex Pro mouse cytokine 13-plex assay (Millipore). 
Immune cell analysis 
 Mice were sacrificed 7 days after inoculation and perfused with PBS. The inoculated foot 
was disarticulated at the ankle without fracturing the bone. Cutaneous and subcutaneous tissue 
were everted but still attached to the distal foot and digits during digestion. Tissues were incubated 
for 2 hours at 37°C in digestion buffer [RPMI, type I collagenase (2.5 mg/ml) (Sigma), DNase I 
(10 mg/ml) (Sigma), 15 mM Hepes, 10% FBS]. Digested tissues were passed through a 70-μm cell 
strainer. The number of viable cells was quantified by trypan blue staining. Isolated cells were 
incubated with anti-mouse CD16/CD32 (Clone 93; BioLegend) for 10 min at 4°C and then surface-
stained in PBS containing 5% FBS for 30 min at 4°C with the following antibodies: anti–CD3e-
FITC (fluorescein isothiocyanate) (eBioscience), anti–CD4-PE (phycoerythrin) (BD Biosciences), 
anti–CD8a-PerCP/Cy5.5 (BioLegend), anti–NK1.1-PE/Cy7 (BioLegend), anti–CD45-Brilliant 
Violet 605 (BioLegend), anti–Ly6C-Brilliant Violet 421 (BD Biosciences), anti–Ly6G–Alexa 
Fluor 700 (BioLegend), and anti–CD19-APC/Cy7 (BioLegend). Cells were washed and incubated 
at room temperature for 30 min in Foxp3 Fixation/Permeabilization buffer (eBioscience). The 
fixed cells were washed with Permeabilization buffer (eBioscience) and stained in 
Permeabilization buffer overnight at 4°C with anti–Foxp3–Alexa Fluor 647 (BioLegend). Cells 
were run on a LSR II (Becton Dickinson) flow cytometer and analyzed using BD FACSDiva and 
FlowJo software. 
Statistical analysis 
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 All data were analyzed with GraphPad Prism software. For viral burden analysis, cytokine 
measurements, and numbers of infiltrating leukocytes, data were analyzed by the Mann-Whitney 
test, ANOVA, or Kruskal-Wallis test with a Dunn’s post hoc analysis. P < 0.05 indicated 
statistically significant differences. 
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3.6 Figures 
 
Figure 3.1 Screen of candidate oral and biological DMARDs for treatment of acute CHIKV arthritis in 
mice 
Mice were inoculated with 103 FFU of CHIKV via a subcutaneous route. (A) Schematic depicting the two 
controls and six treatment arms. Medications and doses were methylprednisolone (0.5 mg/kg, IP) daily 
from 3-7 dpi, naproxen (10 mg/kg, IP) daily from 3-7 dpi, methotrexate (0.3 mg/kg, IP) once weekly (2 
doses: 3, 10 dpi), etanercept (300 μg, IP) 1 dose on day 3, CTLA4-Ig (300 μg, IP) 1 dose on day 3, and 
tofacitinib (50 mg/kg) oral gavage daily from 3-7 dpi. For subsequent studies of CTLA4-Ig, an isotype 
control antibody was used. (B) Experimental design included treatment at 3 dpi and harvests on 7 and 28 
dpi for the indicated analyses. Throughout the time course, foot swelling was measured using digital 
calipers. (C) Foot swelling (area in mm2) on day 7 compared to day 0 for all injected therapies. (D) Foot 
swelling over time for injection control and CTLA4-Ig–treated animals. (E) Foot swelling on day 7 
compared to day 0 for tofacitinib and oral vehicle control. (F) Foot swelling over time for oral vehicle 
control and tofacitinib-treated animals. (G to J) qRT-PCR analysis of viral RNA levels in the left and right 
ankles at 7 and 28 dpi for all treatment groups. Results in (C) to (J) are from at least two independent 
experiments with n = 28 per treatment group for measurement data from days 0 to 7 and n= 7-8 for viral 
burden analysis on days 7 and 28. Data represent the means (C to F) or median (G to J) ± SEM. *P < 0.05, 
**P < 0.005, ****P < 0.0001 [two-way ANOVA for analysis of swelling curves, Mann-Whitney for day 7 
tofacitinib analysis, and Kruskal-Wallis with Dunn’s post hoc analysis for day 7 injected medication and 
viral burden analysis].  
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Figure 3.2 Combination therapy with CTLA4-Ig and an anti-CHIKV human mAb ameliorates acute 
CHIKV arthritis in mice 
Mice were inoculated with 103 FFU of CHIKV via a subcutaneous route. (A) Foot swelling (area in mm2) 
from day 0 through day 15 in mice receiving at day 3 a single IP injection of 600 μg of isotype control 
antibody, 300 μg of CTLA4-Ig, 300 μg of anti-CHIKV mAb (4N12), or a combination of 300 μg of CTLA4-
Ig and 300 μg of anti-CHIKV mAb. Data are pooled from two independent experiments (n = 15 to 19 
animals per group). (B) Representative photographs of ipsilateral foot swelling in the control mAb or 
combination therapy (CTLA4-Ig + anti-CHIKV mAb) groups. Data represent the means ± SEM. **P < 
0.005, ****P < 0.0001 (two-way ANOVA with multiple comparisons).  
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Figure 3.3 Viral burden in CHIKV-infected mice treated with CTLA4-Ig and anti-CHIKV mAb 
Mice were inoculated with 103 FFU of CHIKV via a subcutaneous route. Mice received at day 3 a single 
IP injection of 600 μg of isotype control antibody, 300 μg of CTLA4-Ig, 300 μg of anti-CHIKV mAb, or a 
combination of 300 μg of CTLA4-Ig and 300 μg of anti-CHIKV mAb. (A) Infectious virus in joints and 
serum quantitated by focus-forming assay on day 5 after infection. (B and C) Real-time qRT-PCR analysis 
of viral RNA levels in the ipsilateral (left) and contralateral (right) ankles and left wrist at days 7 and 28 
after infection. Results are pooled from two independent experiments with n = 10 per treatment group for 
viral RNA data and n = 8 for focus-forming assay data. Data represent the median ± SEM. *P < 0.05, **P < 
0.005, ***P < 0.0005 (Kruskal-Wallis with Dunn’s post hoc analysis). 
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Figure 3.4 Cytokine and chemokine analysis in CHIKV-infected mice treated with CTLA4-Ig and anti-
CHIKV mAb 
Mice were inoculated with 103 FFU of CHIKV via a subcutaneous route. Mice received at day 3 a single 
IP injection of 600 μg of isotype control antibody, 300 μg of CTLA4-Ig, 300 μg of anti-CHIKV mAb, or a 
combination of 300 μg of CTLA4-Ig and 300 μg of anti-CHIKV mAb. (A to I) Cytokine and chemokine 
levels on day 7 in the ipsilateral foot of mice in each treatment group. Analytes included CXCL10 (A), 
MIP-1β (B), MCP-1 (C), KC (D), RANTES (E), CXCL9 (F), MIP2 (G), IL-1β (H), and TNF-α (I). Results 
are pooled from two independent experiments with n = 8 mice per treatment group. Data represent the 
means ± SEM. *P < 0.05, **P < 0.005 (Kruskal-Wallis with Dunn’s post hoc analysis). 
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Figure 3.5 Representative H&E staining of the ipsilateral midfoot joints in CHIKV-infected mice 
treated with CTLA4-Ig and anti-CHIKV mAb 
(A to F) Mice were inoculated with either PBS (A; mock) or 103FFU of CHIKV (B to F) via a subcutaneous 
route. Animals were sacrificed, and histology of the ipsilateral foot was performed on day 7 after infection. 
CHIKV-infected mice received at day 3 a single intraperitoneal injection of 600 μg of isotype control 
antibody (B), 300 μg of anti-CHIKV mAb (C), 300 μg of CTLA4-Ig (D), or a combination of 300 μg of 
CTLA4-Ig and 300 μg of anti-CHIKV mAb (E). The number of inflammatory cells per HPF in the midfoot 
synovial space was quantitated in a blinded fashion (F). Results are representative of at least two 
independent experiments with n = 4 per treatment group and two sections assessed per foot. Scale bars, 200 
μm. Yellow arrows, moderate to severe synovitis; white arrows, absent or mild synovitis *P < 0.05, 
****P < 0.0001 (Kruskal-Wallis with Dunn’s post hoc analysis). 
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Figure 3.6 Flow cytometry analysis of infiltrating leukocytes in the feet of mice on day 7 after infection 
with CHIKV 
Mice were inoculated with 103 FFU of CHIKV via a subcutaneous route. Mice received at day 3 a single 
intraperitoneal injection of 600 μg of isotype control antibody, 300 μg of CTLA4-Ig, 300 μg of anti-CHIKV 
mAb, or 300 μg of CTLA4-Ig and 300 μg of anti-CHIKV mAb. (A) Gating strategy showing subpopulations 
of live CD45+ cells, including the percentages of CD11b+Ly6C+ inflammatory monocytes, followed by 
CD3 and CD4 expression (lower panel) in the remaining Ly6C-negative cells (red arrow) isolated from the 
feet of mice from each treatment group. (B to G) Total number of isolated CD45+, CD4+, CD8+, 
Ly6C+CD11b+, NK1.1+, and Ly6G+ cells from the feet of CHIKV-infected mice in each treatment group. 
Results are pooled from two independent experiments with 4 to 5 mice per group in each experiment. Data 
represent the means ± SEM. **P < 0.005, ***P < 0.0005, ****P < 0.0001 (Kruskal-Wallis with Dunn’s 
post hoc analysis). 
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Figure 3.7 Clinical assessment of the response to CTLA4-Ig treatment in CHIKV-infected WT and 
TCRβδ−/− mice 
Mice were inoculated with 103 FFU of CHIKV via a subcutaneous route. (A and B) Foot swelling in WT 
(A) and TCRβδ−/− (B) mice from day 1 through 7 in mice receiving at day 3 a single IP injection of 300 μg 
of isotype control antibody or 300 μg of CTLA4-Ig. (C) Increase in foot swelling (area in square millimeter) 
on day 7 after infection in control- and CTLA4-Ig–treated WT and TCRβδ−/− mice. ns, not significant. 
Measurements were conducted in a blinded fashion. Results are pooled from two or three independent 
experiments with total n = 16 to 18 per group for WT animals and n = 12 to 13 per group 
for TCRβδ−/− animals. Data represent the means ± SEM. **P < 0.005 (two-way ANOVA with multiple 
comparisons for swelling curves; Mann-Whitney test for day 7 swelling). 
  
89 
 
Figure S3.1 RANKL and OPG expression in CHIKV-infected joints 
Mice were inoculated with 103 FFU of CHIKV via a subcutaneous route. At day 3 after infection, a single 
IP injection of 600 μg of isotype control antibody, 300 μg of CTLA4-Ig, 300 μg of anti-CHIKV mAb, or a 
combination of 300 μg CTLA4-Ig and 300 μg anti-CHIKV mAb was administered. On day 7 after infection, 
RNA was isolated from the left foot. RANKL (A) and OPG (B) expression were measured by qRT-PCR 
and normalized to GAPDH. Data were pooled from two independent experiments (n = 10 animals per 
group) and analyzed by ANOVA with a multiple comparisons test. P > 0.1 for all groups. 
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Figure S3.2 Foot swelling with CTLA4-Ig therapy administered before or during CHIKV infection 
Five week-old mice were inoculated with 103 FFU of CHIKV via a subcutaneous route. (A) Foot swelling 
(area in mm2) from day 0 through day 7 in mice receiving a single IP injection of 300 μg of isotype control 
antibody or 300 μg of CTLA4-Ig at day -1 or day 3. Data are pooled from two independent experiments (n 
= 9 or 10 animals per group). Data represent the mean ± SEM. **, P < 0.005; **** P < 0.0001 (2-way 
ANOVA with multiple comparisons test). 
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Figure S3.3 Flow cytometry analysis of APC activation in the spleen and ankles of mice on day 7 after 
infection with CHIKV 
Mice were inoculated with 103 FFU of CHIKV via a subcutaneous route. Mice received at day 3 a single 
IP injection of 300 μg of isotype control antibody 300 μg of CTLA4-Ig on either day -1 or day 3 after 
infection. (A) Representative contour plots showing the percentages of CD11c+MHCII+ dendritic cells and 
CD11bintF4/80+ macrophages in the left foot and spleen of infected animals from each treatment group. (B) 
Representative histograms (left panel) and geometric mean fluorescence intensity of CD86 expression on 
CD11c+MHCII+ dendritic cells and CD11bintF4/80+ macrophages in the left foot and spleen of infected 
animals from each treatment group. Results are pooled from two independent experiments with 3 to 4 mice 
per group per experiment. No statistically significant differences were observed in the treatment groups 
(Kruskal-Wallis with Dunn’s post-hoc analysis). 
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Chapter 4 
Summary and Future Directions 
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4.1 Summary 
 CHIKV has rapidly emerged as a global pathogen in little more than a decade, ultimately 
infecting millions of people worldwide. Infected individuals experience debilitating myalgia and 
polyarthritis that can persist for months to years after infection. An IFN-I response is absolutely 
required to control CHIKV and other alphavirus infections. IFN-Is are composed of 14 IFN-α 
subtypes and single forms of IFN-β, IFN-ε, IFN-κ, and IFN-ω, and despite their central role in 
protection against CHIKV, little is known about the biological roles of individual IFN-I subtypes 
during viral infection. 
 We evaluated the pathogenesis of CHIKV in mice that lack either IFN-α (through IRF7 
knockout or IFN-α blocking mAb) or IFN-β (through IFN-β knockout or IFN-β blocking mAb). 
We demonstrated that loss of IFN-α greatly impacted CHIKV replication and dissemination. In 
contrast, loss of IFN-β exacerbated acute CHIKV disease but without having much impact on viral 
loads, suggesting a protective immunomodulatory role. We demonstrated that IFN-β is protective 
in CHIKV infection by signaling on nonhematopoietic cells and ultimately limiting neutrophil 
recruitment into site of inflammation. Further, the increased clinical disease observed in IFN-β 
knockout mice could be rescued with neutrophil depletion. This is distinct from the 
immunomodulatory action of IFN-β during LCMV infection, where IFN-β promotes viral 
persistence, presumably by increasing infection of CD8α– DCs. Our findings support the growing 
evidence of differential functions for IFN-α versus IFN-β and also highlight that distinct 
mechanisms can underlie these differences depending on the biological context. 
 Pathogenesis of CHIKV is still poorly understood but is thought to reflect an interplay 
between viral replication and a detrimental immune response. Currently, no approved treatment is 
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effective in preventing or controlling CHIKV infection or disease. We examined the efficacy of 
several U.S. Food and Drug Administration (FDA)–approved RA therapies in a mouse model of 
CHIKV infection. We identified two DMARDs (CTLA4-Ig and tofacitinib) with efficacy during 
acute CHIKV arthritis. In particular, CTLA4-Ig, when paired with the neutralizing anti-CHIKV 
human mAb 4N12, was highly effective at reducing joint inflammation, periarticular swelling, 
migration of inflammatory leukocytes, and infection even when administered several days after 
virus inoculation. The concept of combination antiviral and immunomodulatory therapy is a 
unique approach for the treatment of infectious diseases. The near-complete effectiveness of 
combination therapy in our mouse model of acute CHIKV arthritis has implications for treatment 
of other viral infections in which both virus- and immune-mediated pathology result in morbidity 
and mortality (for example, influenza and severe acute respiratory syndrome coronavirus). Given 
the large number of clinically available biological and small molecular DMARDs, this work may 
provide greater impetus for studies that test combination antiviral and immunomodulatory 
therapies for the treatment of infectious diseases. 
 Collectively, these studies highlight that both viral replication and the host immune 
responses play important roles in CHIKV pathogenesis. The host immune response has evolved 
mechanisms, including IFN-I and likely others, that impede both host- and viral-mediated 
pathology. Continued pursuit of delineating host-pathogen interactions will be paramount in 
developing effective therapeutic and vaccine strategies to combat emerging tropical diseases, 
which remain a global health and economic burden. 
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4.2 Future Directions 
 Our findings demonstrate that IFN-α and IFN-β have distinct protective activities during 
acute CHIKV infection. IFN-α appears to be more important for initiating antiviral responses, 
whereas IFN-β functions as an immunomodulatory molecule to indirectly limit neutrophil-
mediated pathology. Additionally, our findings suggest that nonhematopoietic cells are central to 
IFN-I mediated control of CHIKV arthritis, consistent with previously published bone marrow 
chimera experiments. While these findings have taken important steps to increase our 
understanding of IFN-I biology and CHIKV pathogenesis, there are several new questions raised 
from these observations. The following sections identify some of these outstanding questions and 
discuss future experiments that will aid in further characterizing the actions of IFN-I subtypes 
during CHIKV infection. 
4.2.1 When and where are IFN-I subtypes induced during CHIKV infection? 
 Studies of IFN-ε demonstrated that the cell type and context of expression can dramatically 
impact the function of an IFN-I subtype. IFN-ε is the only subtype demonstrated to not be regulated 
by PRR pathways, but rather, it is constitutively expressed by the epithelium of reproductive 
organs and further regulated by sex hormones137. Likely a consequence of its unique regulation, 
IFN-ε is the only type I IFN subtype shown to play a protective role against Chlamydia infection, 
whereas the other subtypes may worsen disease137,138. There is very little known about differential 
expression of IFN-α versus IFN-β in vivo, and their differential properties during LCMV and 
CHIKV infection may be due to the timing and location of expression. It may be that loss of IFN-
α greatly impacts viral replication because the IFN-α’s, but not IFN-β, are primarily expressed 
near the cells that are targeted by CHIKV. With the tools currently available, the best way to 
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discriminate between the IFN-I subtypes is at the transcript level, through the use of sequence 
specific probes. Use of fluorescent in situ hybridization (FISH) for IFN-β, IFN-α4, and at least one 
of the IFN-α subtypes induced downstream of IFN-α4/β signaling (e.g. IFN-α2), paired with cell 
identifying marker staining would determine the specific cells expressing the various IFN-I 
subtypes. Using mRNA FISH detection has its caveats, since transcriptional induction is not 
equivalent to cytokine activity, but even with these limitations, this type of in vivo analysis has not 
been performed before and would still be informative. 
 Since transcriptional regulation does not perfectly correlate to cytokine activity, tools that 
visualize or detect the different IFN-I subtypes at the protein level in vivo are greatly needed. The 
advent of CRISPR-Cas9 technology has enabled precise targeted editing or deletion of genes with 
rapid results, and Washington University has several core facilities offering these services. Using 
this technology we could develop several mice strains that express fluorescently tagged IFN-I 
subtypes. IFN-β, IFN-α4, and a non-initiating subtype, like IFN-α2, would be the important 
subtypes to initially analyze. Tagging the IFN-I proteins themselves would avoid the caveats of 
relying on transcription as a readout of activity or expression, but may alter the activity of the 
protein. Most of the available fluorescent labels are much larger than the IFN-I subtypes, so 
extensive in vitro characterization would be required to first ensure that the tagged IFN-I is still 
functional. Alternatively, we could develop mice that fluorescently report induction of a particular 
IFN-I subtype. This scheme would have caveats similar to the FISH transcript detection method, 
but would avoid altering the function of the protein and might have better sensitivity compared to 
FISH. While there are caveats and limitations for each reporter mouse scheme, both methods 
would bypass the brute force screening needed to generate IFN-I subtype specific mAbs. 
Altogether, these types of tools will allow spatial and temporal evaluation of IFN-I subtype 
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induction during a viral infection in vivo, and may reveal novel properties that previous expression 
readouts from whole tissues might have missed. 
4.2.2 How is IFN-α limiting CHIKV replication and dissemination? 
 The increase in viral replication and spread with the loss of IFN-α could be due to 
alterations in tropism, such as spread to immune cells, or be due to increased infection of cells 
normally infected by CHIKV (muscle and fibroblasts). This would be determined by 
immunohistochemistry (IHC) analysis with CHIKV and CD45 co-staining of the ipsilateral foot 
at several time points during acute infection. Given the results with Vav-Cre expressing mice (Fig. 
2.4), we expect to see increased CHIKV staining in CD45– cells in IRF7-KO mice and mice treated 
with anti-IFN-α mAb compared to WT mice, and we anticipate similar CHIKV staining between 
WT and IFN-β-KO mice, given the similarity in viral loads (Fig. 2.3A). These data will allow us 
to more conclusively say that nonhematopoietic cells are the key cell types responding to IFN-I 
during acute CHIKV infection. An important next question would then be what is the impact of 
loss of IFN-I signaling on these specific cell types during CHIKV infection in vivo? To address 
this, we would cross the IFNARfl/fl mice to Ckm (muscle creatine kinase) Cre mice, which target 
skeletal and cardiac muscle,  or Col1a2 (collagen, type 1, alpha 2) Cre mice, which target many 
fibroblast cell types205,206. These types of experiments have not been done before and would allow 
us to study the impact of IFN-I responses in relevant cell types in vivo. 
 IFN-I ultimately exert their biological effects through the induction and regulation of ISGs. 
There have only been a handful of ISGs described to have anti-CHIKV activity in vitro and in 
vivo, including viperin, PKR, GADD34, IFITM3, and tetherin/BST2121,123–127. ISG15 has also been 
described to play a protect role during CHIKV infection, but rather than functioning to limit viral 
replication, as it does in several other viral systems, the absence of ISG15 during neonatal CHIKV 
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infection resulted in increased lethality from a cytokine storm-like phenotype58. There have been 
examples of differential ISG induction by IFN-β compared to IFN-α subtypes in vitro. For 
example, IFN-β was shown to have more potent osteoclastogenesis activity by its preferential 
upregulation of CXCL11 compared to IFN-α2135. Cell type-dependent effects are thought to be the 
result of variation in IFNAR surface expression and composition of downstream effector 
molecules, such as STATs157. In order to fully understand how IFN-α and IFN-β display distinct 
functions in vivo, a more comprehensive evaluation of the ISGs induced downstream of IFN-α 
versus IFN-β in the relevant cell types (such as muscle) is warranted. Our lab has established 
protocols for culturing primary synovial fibroblasts and myofibers. RNAseq analysis of infected 
primary cell cultures in the presence or absence of anti-IFN-α or anti-IFN-β blocking mAb will 
allow us to determine if there are IFN-α- or IFN-β-dependent sets of ISGs induced in response to 
CHIKV infection. Furthermore, we will be able to evaluate if ISG induction or subtype differences 
display cell type specificity (synovial fibroblasts versus myofibers). 
4.2.3 What is the role of neutrophils in the pathogenesis of CHIKV-infected 
IFN-β-KO mice? 
 Neutrophils are essential for the increased clinical disease observed in the IFN-β-KO mice 
since the phenotype could be rescued with neutrophil depletion. IRF7-KO mice were not originally 
included in the analysis of cellular infiltrates and cytokine and chemokine induction because the 
drastic difference in viral load between IRF7-KO and WT mice would make it challenging to 
interpret the data. Nevertheless, we did run IRF7-KO samples as we were analyzing the WT and 
IFN-β-KO samples, and Irf7-/- mice not only recruited more neutrophils but also showed fewer 
inflammatory monocytes compared to WT mice (Fig. 4.1A). In contrast with what we observed in 
IFN-β-KO mice (Figure 2.6), analysis of cytokine and chemokine induction in the ipsilateral foot 
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of IRF7-KO mice revealed elevated CXCL1 and substantially increased G-CSF levels (Fig. 4.1B). 
The likely scenario in the IRF7-KO mice is that elevated viral burden is driving increased 
inflammation, cell death, and edema, which collectively alter cellular recruitment. Importantly, 
despite the increase in neutrophil number, neutrophil depletion had no impact on foot swelling in 
IRF7-KO mice (Fig 2.7), which raises the idea that increased neutrophil number alone might not 
be responsible for the phenotype in the IFN-β-KO mice. Indeed, we observed elevated IL-9 levels, 
and one study demonstrated that synovial fluid from RA patients could increase the activation and 
survival of neutrophils ex vivo, but this effect was lost when anti-IL-9 neutralizing antibody was 
added161. To determine if the neutrophils themselves are altered in the IFN-β-KO mice, flow 
cytometry analysis of neutrophil activation markers and apoptosis, such as iNOS/NOS2 
(eBiosciences) or Annexin V staining, would be used. 
 To understand the molecular mechanism of IFN-β-mediated protection during CHIKV 
infection, we need to know how many steps are between IFN-β and altered neutrophil recruitment 
and/or function. First, we need to determine if IL-9 is directly involved in the pathogenesis of 
CHIKV infection in IFN-β-KO mice, which could be determined by administering a commercially 
available anti-IL-9 neutralizing mAb (9C1; Bio X Cell) to IFN-β-KO mice during CHIKV 
infection207. If IL-9 is directly involved in the neutrophil phenotype, we should see complete or 
partial alleviation of increased foot swelling and neutrophil recruitment in the IFN-β-KO mice. If 
this turns out to be the case, the next question would be which cells are making IL-9? To answer 
this, we would infect IL-9 fate reporter mice [available at Medical Research Council (MRC), Mill 
Hill, UK] with CHIKV in the presence of anti-IFN-β blocking mAb or isotype control antibody. 
In a model of lung inflammation, ILC2s were identified as the predominant source of IL-9173, and 
this would be consistent with the timing of elevated IL-9 in the IFN-β-KO mice (2 dpi) (Fig. 2.6). 
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 The potential involvement of ILC2s in the pathogenesis of CHIKV in IFN-β-KO mice 
again raises the question of which cell types are responding to IFN-β? Based on the Vav-Cre+ 
IFNAR1fl/fl mice (Fig. 2.4), we believe that IFN-β is signaling on nonhematopoietic cells. ILC2s 
are known to produce IL-9 when stimulated with IL-25, IL-33, and thymic stromal lymphopoietin 
(TSLP), which are typically secreted by damaged epithelium barriers174. Synovial fibroblasts 
isolated from RA patients have been shown to produce both IL-33 and TSLP175,176. So if we 
determine that IL-9 and ILC2s are directly involved in the pathogenesis in the IFN-β-KO mice, 
determining the in vivo source of IL-33, IL-25, or TSLP would identify potential cellular targets 
of IFN-β. IFN-γ has previously been shown to downregulate IL-33 induction in lung fibroblasts in 
a STAT1-dependent manner208, and IFN-I signaling is also able to activate phosphorylated STAT1 
homodimers104. These data suggest that IFN-β-mediated regulation of IL-33 is not outside the 
realm of possibility. We would use IHC or immunofluorescence co-staining of IL-33 or IL-25 with 
cell identifying markers to determine the cells making these cytokines in ipsilateral foot sections 
of WT and IFN-β-KO mice. 
 If flow cytometry does not reveal differences in neutrophil activation and if IL-9 
neutralization is protective, we would need to employ RNAseq analysis of isolated neutrophils 
(Ly6G+ enrichment, Miltenyi) to understand how neutrophils are contributing to the pathogenesis 
in IFN-β-KO mice. Alternatively, if IL-9 blockade has no effect, we would perform RNAseq on 
the whole foot tissue to delineate the mechanisms underlying the increased neutrophil recruitment 
and/or function in the IFN-β-KO mice compared to WT and IRF7-KO mice. Collectively, these 
experiments will yield a more complete picture of how loss of IFN-β activity leads to neutrophil-
mediated immunopathology during CHIKV infection. 
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4.2.4 What roles do IFN-I play during chronic CHIKV disease? 
 The pathogenesis of chronic CHIKV disease is still poorly understood. CHIKV RNA, but 
not infectious virus, persists in the joints and musculoskeletal tissues of patients and animals 
infected with various strains of CHIKV52,55,66. This RNA might serve as a PAMP and cause chronic 
symptoms by continuously activating the immune system. Consistent with this paradigm, 
microarray analysis of the ipsilateral foot of WT mice at 30 days post infection showed not only 
elevated expression of IFN-I-related genes, such as IRF7, IFNAR1, and IFN-β, but also 
downregulation of known IFN-I negative regulators SOCS1 and TRIM2455. IFN-I can have 
detrimental effects during some chronic infections, such as LCMV, by promoting constant 
inflammation, but IFN-I are also important for augmenting protective adaptive immune responses, 
like the generation of neutralizing antibodies151,152,209. Because Ifnar1-/- mice die so quickly 
following CHIKV infection, most studies have focused on understanding the roles of IFN-I during 
acute CHIKV pathogenesis and do not examine chronic disease. 
 To determine the impact of loss of IFN-α or IFN-β on chronic CHIKV disease, we infected 
WT, IFN-β-KO, and IRF7-KO mice with 103 pfu CHIKV via a subcutaneous route and then 
sacrificed the mice at 28 dpi for persistent CHIKV E1 RNA analysis by qRT-PCR. We found that 
IRF7-KO mice had significantly more chronic CHIKV E1 RNA copies present in the ipsilateral 
ankle (Fig. 4.2A, left panel, P < 0.01), whereas IFN-β-KO mice displayed no change in chronic 
RNA compared to WT mice (Fig. 4.2A, left panel, P > 0.05). Additionally, IRF7-KO mice had 
substantially more persistent RNA in the contralateral ankle (Fig. 4.2A, right panel, p < 0.0001), 
and in contrast, the IFN-β-KO mice showed only a modest increase in RNA burden compared to 
WT mice, which was to a much lesser degree than the increase observed in the IRF7-KO mice 
(Fig. 4.2A, right panel, P < 0.01). Importantly, administering anti-IFN-α or anti-IFN-β mAb at 1 
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day before infection and again at 1 dpi phenocopied the IRF7-KO and IFN-β-KO mice, 
respectively (Fig 4.2B). These data are consistent with what we observed during acute infection, 
and the IFN-α’s seem to be more important in limiting persistent CHIKV RNA during chronic 
disease compared to IFN-β. 
 IFN-I are also known to augment antibody production and isotype switching in B cells108. 
Neutralizing antibodies are important for clearing infectious virus and limiting persistent CHIKV 
RNA, so the elevated CHIKV RNA could either be due to the increased infection of cells early 
during infection or be due to a failure to properly control or clear the RNA through adaptive 
immune responses210. To assess these possibilities, we infected WT mice with CHIKV and then 
administered anti-IFN-α mAb or isotype control antibody at 2 dpi, which is when elevated viral 
load is first observed in the IRF7-KO mice but before the generation of adaptive immune responses 
(Fig. 2.3A). Blockade of IFN-α at 2 dpi had no impact on foot swelling compared to isotype control 
treated mice (Fig. 4.2C), which is in stark contrast to the severe increase in foot swelling seen with 
the day -1/+1 blockade regimen (Fig. 2.1B). IFN-α blockade at day 2 also showed no increase in 
the viral RNA burden in the ipsilateral ankle (Fig. 4.2D, left panel). Detailed analysis of acute 
infectious virus with this blockade regimen still needs to be performed, but these data imply that 
IFN-α acts within the first 48 hours to limit clinical foot swelling, presumably through limiting 
viral replication at the site of infection. Furthermore, the antiviral activity of IFN-α during the first 
48 hours of infection is able limit persistent CHIKV RNA in the ipsilateral ankle at 28 dpi. In 
contrast, the contralateral ankle still showed elevated persistent CHIKV RNA with day 2 blockade 
of IFN-α (Fig. 4.2D, right panel, P < 0.0001), suggesting that IFN-α activity is needed beyond 2 
dpi to limit CHIKV dissemination. 
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 The increased persistent viral RNA from loss of IFN-α could be due to more cells harboring 
CHIKV RNA during chronic time points. Our lab has developed a system to permanently label 
cells that survive CHIKV infection using a Cre-expressing CHIKV strain and fluorescent fate-
reporter mouse. Using this system in conjunction with anti-IFN-α and anti-IFN-β blockade, we 
will be able to assess how many and what types of cells are surviving CHIKV infection and how 
loss of IFN-α or IFN-β impacts those cells populations. No difference in marked (Cre+) cells could 
indicate that IFN-α is impacting the amount of virus produced by an infected cell, rather than 
limiting the number of cells infected. Tropism studies during acute infection (discussed in section 
4.2.2), would aid in interpreting the results from these chronic experiments. Much more work is 
needed to characterize the immune and viral factors contributing to chronic CHIKV disease, and 
there are limitations in using mice to study a human virus. However, these studies will still be 
beneficial in understanding how IFN-I subtypes function during chronic CHIKV pathogenesis. 
4.2.5 Are there dual protective and detrimental roles for IFN-β during 
CHIKV infection? 
 Of all the IFN-I subtypes, IFN-β has the highest known natural affinity for IFNAR, and as 
such has been described as the most potent IFN-I subtype for a number of functions, including 
anti-proliferative and pro-apoptotic activities. In particular, IFN-β has potent immunomodulatory 
activity and is used as a therapeutic agent in multiple sclerosis, providing beneficial 
immunomodulatory effects171. In contrast, recent work with LCMV persistent infection 
determined that IFN-β was detrimental and promoted viral persistence150. Blockade of IFN-β, but 
not IFN-α, improved antiviral T cell responses and lead to clearance of LCMV, recapitulating what 
was observed with IFNAR1 blockade150–152. We did not see a significant change in persistent 
CHIKV RNA at 28 dpi with the loss of IFN-β (Fig. 4.2A, 4.2B), but given this history of IFN-β in 
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mediating chronic inflammation, we expanded our evaluations to ensure we were not missing a 
phenotype. 
 When we performed our chronic CHIKV experiments for WT, IFN-β-KO, and IRF7-KO 
mice, we also collected samples for histological analysis. We had a blinded pathologist score the 
day 28 H&E slides, and we were surprised to see that 100% of the IFN-β-KO mice received a 
score of 0 (no inflammation), whereas the WT and IRF7-KO mice received an average score of 
around 1 (mild inflammation) (Fig. 4.3A). This is preliminary data and needs to be repeated to 
increase the sample size, but this was a striking observation. For LCMV infection, the clue that 
prompted evaluation of a detrimental role for IFN-β during chronic infection came from evaluating 
IFN-α versus IFN-β induction. Infection with clone 13 LCMV infection, which yields persistent 
infection, revealed a substantial elevation in IFN-β induction compared to the amount that is 
induced during infection with the Armstrong strain of LCMV, which yields an acute infection150. 
With this in mind, we next evaluated the induction of IFN-β, IFN-α4, and the IFN-α subtypes that 
are induced downstream of IFN-α4/β signaling (pan non-IFN-α4) by qRT-PCR at 12 hours post 
infection and 28 dpi. Surprisingly, we found that IFN-I induction was much higher at the chronic 
time point than at the acute time point, and IFN-β had the highest chronic expression among the 
subtypes analyzed (Fig. 4.3B). A hallmark for detrimental IFN-I responses is sustained elevated 
expression, and our preliminary data suggest that this might be the case during CHIKV infection. 
 We know from our acute CHIKV studies, that IFN-β-KO mice have elevated neutrophil 
recruitment at 2 dpi. We next asked what would happen if we blocked IFN-β at around the time it 
had already performed this beneficial immunomodulatory function. We infected WT mice and 
then administered anti-IFN-β mAb at 2 dpi, and we monitored the mice for clinical foot swelling 
and then sacrificed them at 28 dpi for persistent RNA analysis. We found that day 2 IFN-β 
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blockade promoted quicker resolution of foot swelling compared to isotype control treated mice 
(Fig. 4.3C). Persistent RNA analysis at 28 dpi revealed no change in viral RNA burden, indicating 
that again, IFN-β seems to be modulating pathology, but not viral load (Fig. 4.3D). It is worth 
noting that the protective foot swelling phenotype seen with day 2 IFN-β blockade is modest 
compared to other beneficial treatments, such as depleting CD4+ T cells79. However, these 
preliminary data suggest that IFN-β may be playing a detrimental role during the resolution of 
inflammation. We performed preliminary FACS analysis of immune infiltrates at 7 dpi in control 
treated mice or mice that received anti-IFN-β at 2 dpi, and we did not see any drastic changes in 
numbers for the expected immune cell populations at this time point, such as CD4+ T cells, CD8+ 
T cells, NK cells, macrophages, monocytes, or neutrophils (data not shown). 
 There have been very few studies performed to characterize the resolution phase of clinical 
CHIKV disease. At this point, we can only speculate why IFN-β has this paradoxical dual 
protective and pathogenic role. It could be that the presence of IFN-β at later time points skews 
the activation state of certain cell types that inhibits their ability to promote resolution of 
inflammation. Redesigning our flow cytometry panel to allow for more careful evaluation of the 
various cell populations that may be involved in resolution inflammation, such as myeloid 
suppressor cells or regulatory T cells, will be important in determining how IFN-β is mediating 
these detrimental effects. There are so many permeations of myeloid cell phenotypes, that standard 
flow cytometry may be insufficient to capture the phenotype. If we are unable to identify altered 
cell recruitment or activation by flow cytometry, then we may need to use CYTOF (mass 
cytometry) analysis to parse this phenotype. 
 Collectively, the data from acute CHIKV disease and these preliminary findings with 
chronic CHIKV disease suggest that the biological activity of IFN-β is more complicated than 
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originally thought. Its protective versus pathogenic functions are likely related to the timing, 
concentration, and cellular source of its expression, as well as its unique signaling potential as the 
highest affinity IFN-I subtype. IFN-β is administered intramuscularly or subcutaneously as a 
treatment for multiple sclerosis, and thus, CHIKV is a relevant model to study the functions of 
IFN-β, given the route of infection and tissues and cell types involved in its pathogenesis. Further 
delineation of the actions of IFN-β during acute and persistent CHIKV disease will likely yield 
important insight into its potential use as a therapeutic agent or target. 
4.3 Materials and Methods 
Mice 
 All animal experiments were performed in accordance and with approval of Washington 
University Institutional Animal Care and Use Committee guidelines, and all mouse infection 
studies were performed in an animal biosafety level 3 laboratory. All experiments were performed 
with 4-week-old male mice. C57BL/6J (WT), interferon beta knockout (Ifnb-/-), and IRF7 
knockout (Irf7-/-) mice were bred and maintained in our mouse colony before being transferred to 
the animal biosafety level 3 laboratory for experiments. Ifnb-/- and Irf7-/- mice bred onto the 
C57BL/6J background were generously provided by Michael S. Diamond (Washington University 
School of Medicine). 
Virus experiments 
 A recombinant strain of CHIKV (LR2006 OPY1) was generously provided by S. Higgs 
(Kansas State University) and generated from in vitro transcribed cDNA, as previously 
described177. At 4 weeks of age, mice were inoculated in the left rear footpad with 103 PFU of the 
LR2006 OPY1 strain of CHIKV in a volume of 10 μl. Infected mice were monitored daily for foot 
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swelling with digital calipers for 28 days. At the termination of experiments mice were sedated 
with a ketamine-xylazene cocktail and euthanized, and then perfused via intracardiac injection 
with PBS. Tissues (ipsilateral left ankle and contralateral right ankle) were snap frozen in liquid 
nitrogen and stored at −80°C until processing for viral RNA burden. “Ankle” refers to distal foot 
with the skin and digits removed. Histological analysis and scoring, immune cell infiltrate analysis, 
and cytokine and chemokine analysis are detailed in section 2.5. 
Real-time qRT-PCR analysis 
 RNA was extracted from tissue using TRIzol Reagent and an RNeasy Mini Kit (Qiagen). 
The TRIzol Reagent manufacturer’s protocol was followed up until removal of the RNA-
containing aqueous phase, to which an equal volume of 100% RNase-free ethanol was added. This 
solution was added to the RNeasy column, after which the RNeasy Mini Kit instructions were 
followed. The quantity of CHIKV RNA was determined by qRT-PCR using the TaqMan RNA-
to-CT 1-Step Kit (Applied Biosystems) with an E1-specific primer/probe set203. Absolute copies 
of CHIKV E1 was determined by with a copy number standard curve generated from CHIKV 
genomic RNA synthesized in vitro. Copy number was calculated using an online program (IDT) 
by taking into account the concentration of the RNA (ng/μL), the length of the RNA (11,800 bp 
for CHIKV), and nature of the RNA (ssRNA) (http://scienceprimer.com/copy-number-calculator-
for-realtime-pcr). 
 For IFN-I expression by pRT-PCR, RNA was extracted using a TRIzol and RNeasy Mini 
Kit (Qiagen) hybrid protocol outlined above. Two microliters of the extracted RNA from CHIKV-
infected or mock-infected mice were analyzed by qRT-PCR. An arbitrary standard curve was 
generated for each primer/probe set to generate arbitrary values (SQ) for each gene of interest or 
the housekeeping gene, GAPDH (glyceraldehyde-3-phosphate dehydrogenase). Mock and 
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infected SQ values for the gene of interest and GAPDH values were used to calculate ΔΔCt, and 
normalized fold change was calculated by 2-ΔΔCt. 
IFN-β Fwd: 5’-GGC TTC CAT CAT GAA CAA CAG-3’ Rev: 5’-GTT GAT GGA GAG GGC 
TGT G-3’ Probe: 5’-/56FAM/CTG CGT TCC TGC TGT GCT TCT C/36-TAMSp/-3’ 
IFN-α4 Fwd: 5'-TGT GTG ATG CAG GAA CCT CCT-3' Rev: 5'-GGT ACA CAG TGA TCC 
TGT GG-3' Probe: 5'-/56-FAM/AAG ACT CCC TGC TGG CTG TGA GG/36-TAMSp/-3' 
Pan non-IFNα4 Fwd: 5'-ARS YTG TST GAT GCA RCA GGT-3' Rev: 5'-GGW ACA CAG 
TGA TCC TGT GG-3' Probe: 5'-/56-FAM/CAG GAA CCT CCT CTG ACC CAG GA/36-
TAMSp/-3' 
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4.4 Figures 
 
Figure 4.1 IRF7-KO mice have increased neutrophil recruitment with elevated CXCL1 and G-CSF 
WT and IRF7-KO mice were infected with 103 pfu CHIKV. (A) Flow cytometry analysis of immune 
infiltrates from digested ipsilateral foot tissue at 2 and 3 dpi. (B) Cytokine and chemokine levels in the 
ipsilateral foot were determined using Luminex technology (Millipore). Results are pooled from two 
independent experiments with n = 6-7 mice per group. Data represent the mean ± SEM. *, p<0.05; **, 
p<0.01; ***, p<0.001; ****, p<0.0001 (1-way ANOVA with Tukey’s post-hoc multiple comparisons test).  
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Figure 4.2 IFN-α limits persistent CHIKV RNA in the ipsilateral ankle within the first 48 hours 
following CHIKV infection 
(A) WT, IFN-β-KO, or IRF7-KO mice were infected with 103 CHIKV and sacrificed at 28 dpi for CHIKV 
RNA analysis. (B) WT mice were treated with 1 mg of anti-mouse IFN-α (TIF-3C5), 1 mg anti-mouse IFN-
β (HDβ-4A7), or 1 mg isotype control antibody at 24h prior to and again 24h post infection by IP route and 
then sacrificed at 28 dpi for CHIKV RNA analysis. (C) WT mice were treated with 1 mg of anti-mouse 
IFN-α (TIF-3C5) or 1 mg isotype control antibody at 2 dpi and measured daily for foot swelling and then 
(D) sacrificed at 28 dpi for CHIKV RNA analysis. (A,B, D) Absolute copies of CHIKV E1 was determined 
by qRT-PCR and a standard curve generated from CHIKV genomic RNA synthesized in vitro. Dashed line 
represents the limit of detection. Ips, ipsilateral; contr, contralateral. *, p<0.05; **, p<0.01; ***, p<0.001; 
****, p<0.0001 (1-way ANOVA with Tukey’s post-hoc multiple comparisons analysis for RNA analysis; 
2-way ANOVA with Dunnett’s multiple comparisons for foot swelling).  
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Figure 4.3 IFN-β may have detrimental effects during chronic CHIKV pathogenesis 
(A) WT, IFN-β-KO, or IRF7-KO mice were infected with 103 pfu of CHIKV subcutaneously in the left 
rear foot, and the infected foot was harvested at 28 dpi for histological analysis. H&E slides from d28 were 
scored on a scale of 0 to 3 by a blinded pathologist for overall inflammation, taking into consideration joint 
space inflammation, myositis, and synovitis for scoring. Criteria were: 0, no inflammation; 1, mild 
inflammation; 2, moderate inflammation; 3, severe inflammation. Data are pooled from 2 independent 
experiments with n = 4-5 per group. (B) WT mice were infected with CHIKV and the infected ankle was 
harvested at 12 hours or 28 days post infection for RNA extraction. RT-PCR was used to determine the 
expression of IFN-β, IFN-α, or pan non-IFN-α4 subtypes. n = 4 per group. (C) WT mice were treated with 
1 mg of anti-mouse IFN-β (HDb-4A7) or 1 mg isotype control antibody at 48 hours post infection, and the 
infected foot was measured daily with digital calipers and then (D) sacrificed for CHIKV E1 RNA at 28 
dpi. All data are represented as mean ± SEM, and if no error bar is present that indicates the error is smaller 
than the height of the symbol. The data are pooled from 2 independent experiments with n = 6-7 mice per 
group. *, p<0.05; **, p<0.01; ****, p<0.0001 (2-way repeated measure ANOVA with Dunnett’s post-hoc 
multiple comparisons analysis for foot swelling; 1-way ANOVA with Tukey’s multiple comparisons for 
inflammation score; Mann-Whitney test for CHIKV E1 RNA burden). 
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